Nucleic acid preservation solution and methods of manufacture and use

The nucleic acid preservation composition stabilizes human nucleic acids with minimal microbial contamination, enhancing yield and suitability for diverse analytical techniques and long-term storage.

JP2024163225APending Publication Date: 2024-11-21SPECTRUM SOLUTIONS LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024151398
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-01-16
Filing Date
2024-09-03
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Existing nucleic acid stabilization solutions are not optimal for various analytical techniques, lead to analytical artifacts, and fail to control microbial contamination, resulting in reduced nucleic acid yield and quality.

Method used

A nucleic acid preservation composition comprising an aqueous carrier, chaotropic agent, buffer, chelating agent, surfactant, alcohol, acid, and mucolytic agent, with optional visual indicator, designed to stabilize human nucleic acids while minimizing microbial contamination.

Benefits of technology

The composition enables high yields of human nucleic acids with minimal microbial contamination, suitable for various analytical techniques and long-term storage without freezing, and supports nucleic acid analysis methods like PCR and sequencing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024163225000001_ABST
    Figure 2024163225000001_ABST
Patent Text Reader

Abstract

To provide nucleic acid preserving compositions.SOLUTION: A human nucleic acid preservation composition comprises: 43.92%±10% (w / w) of guanidine thiocyanate; 2.65%±10% (w / w) of tris(hydroxymethyl)aminomethane (Tris); 0.81%±10% (w / w) of ethylenediaminetetraacetic acid (EDTA) or EDTA disodium (salt) dihydrate; 0.279%±10% (w / w) of sodium lauroyl sarcosinate (SLS); 17.73%±10% (w / w) of alcohol comprising a mixture of about 95%±10%(v / v) of ethanol and about 5%±10%(v / v) of isopropanol; 0.093%±10%(w / w) of N-acetyl-L-cysteine; a proper amount (±10%) of hydrochloric acid with a pH of up to about 8.0; and a proper amount, to 100%, of an aqueous carrier comprising filtered, purified, distilled and / or deionized water.SELECTED DRAWING: Figure 1A
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] The present disclosure relates to the preservation of nucleic acids. In particular, the present disclosure relates to compositions and methods for preserving human nucleic acids in biological samples for further analysis.

[0002] Related Technology Nucleic acid can be extracted from biological samples containing cellular and / or acellular nucleic acid. The extracted nucleic acid can be used for various analytical purposes, including genealogy analysis. Extraction of nucleic acid from saliva can be particularly useful because saliva sampling is relatively non-invasive.

[0003] Nucleic acid-containing biological samples often need to be appropriately processed for certain types of nucleic acid analysis. For example, analytical techniques such as nucleic acid sequencing (e.g., next-generation sequencing (NGS)) may require specific processing or pre-processing steps that depend on the particular platform used. In some cases, nucleic acid-containing biological samples may need to be processed to stabilize the sample or its nucleic acids. A stabilizing solution is often added to the nucleic acid-containing biological sample to ensure the survival of some of the nucleic acid until the analysis can be performed.

[0004] Existing stabilization solutions may not be optimal for certain types of analysis techniques or the equipment used to perform them.For example, the stabilization solution formulated for optimal or suitable analysis on one next-generation sequencer may not be optimal or suitable for analysis on another next-generation sequencer.In some cases, improper formulation may cause or result in analytical artifacts, high background signal (or noise), contamination and / or retention of microbial nucleic acid, and / or reduction of the total potential yield of human nucleic acid.

[0005] Existing stabilizing solutions may also be inadequate in controlling microbial survival. Biological samples such as saliva often contain and / or are contaminated with one or more microorganisms (e.g., bacteria, fungi, etc.). These microorganisms contain nucleic acids that can interfere with or be detected together with the nucleic acid of the host or source of the biological sample. Preservation solutions may inadvertently stabilize microbial nucleic acids or even allow microbial proliferation.

[0006] Thus, there remains a need for a universal nucleic acid stabilization solution that is suitable for a variety of analytical techniques and devices and / or a solution that improves the overall nucleic acid yield and sample quality compared to existing products. Summary of the Invention

[0007] The embodiments of the present disclosure solve one or more of the above or other problems in the art with one or more embodiments including nucleic acid preservation, stabilization, and / or preparation compositions, kits containing same, and methods of making and using same. For example, some embodiments of the present disclosure include compositions for preserving, stabilizing, and / or preparing nucleic acid in biological samples. The compositions may be suitable for use in various analytical techniques and devices. The compositions may provide high amounts of nucleic acid for subsequent analysis. For example, the compositions may provide high amounts of human nucleic acid (e.g., DNA), preferably and / or possibly with low amounts of microbial (e.g., bacterial) nucleic acid (e.g., DNA), for subsequent analysis. The compositions may include solutions or aqueous liquids (e.g., aqueous solutions), optionally (light) blue in color, suitable for use in stabilizing human nucleic acid (DNA) and preventing bacterial contamination, as well as for long-term storage.

[0008] The embodiments of the present disclosure include nucleic acid preservation compositions comprising an aqueous carrier, a chaotropic agent, a buffer, a chelating agent, a surfactant, an alcohol, an acid, and a mucolytic agent. The embodiments may further comprise a visual indicator. In some embodiments, the aqueous carrier may be or include water, preferably filtered, purified, distilled, and / or deionized water. In some embodiments, the chaotropic agent may be or include guanidine and / or thiocyanate, preferably guanidine thiocyanate. In some embodiments, the buffer may be or include tris(hydroxymethyl)aminomethane (Tris), preferably Tris-HCl, more preferably Trizma® base. In some embodiments, the chelating agent may be or include ethylenediaminetetraacetic acid (EDTA), preferably as EDTA disodium salt, more preferably EDTA disodium (salt) dihydrate. In some embodiments, the surfactant may be or include sodium lauroyl sarcosinate (SLS). In some embodiments, the alcohol may be or include specially denatured alcohol (SDA) or a mixture of ethanol and isopropanol, preferably a mixture of about 95% (v / v) ethanol and about 5% (v / v) isopropanol, or SDA 3C. In some embodiments, the acid may be or include hydrochloric acid. In some embodiments, the mucolytic agent may be or include N-acetyl-L-cysteine. In some embodiments, the visual indicator may be or include a coloring agent, such as a dye (e.g., FD&C Blue No. 1).

[0009] One embodiment of the present disclosure includes a human nucleic acid storage composition comprising about 43.92% (w / w) of a chaotropic agent (e.g., guanidine thiocyanate), about 2.65% (w / w) of a buffering agent (e.g., Tris), about 0.81% (w / w) of a chelating agent (e.g., disodium EDTA dihydrate), about 0.279% (w / w) of a detergent (e.g., SLS), about 17.73% (w / w) of an alcohol (e.g., SDA 3C), about 0.093% (w / w) of a mucolytic agent (e.g., N-acetyl-L-cysteine), about 0.4% (w / w) of an acid (e.g., hydrochloric acid) or an appropriate amount of acid to a pH of about 8.0, and / or about 34.12% (w / w) of a carrier (e.g., an aqueous carrier comprising filtered, purified, distilled, and / or deionized water) or an appropriate amount of carrier up to 100%. One embodiment may further comprise about 0.00037% (w / w) of a visual indicator (e.g., FD&C Blue No. 1) or its equivalent (e.g., 0.185% (w / w), 0.2% (w / w) visual indicator concentrate (e.g., in water)).

[0010] One or more embodiments include a buffer solution containing 43.92%±10% (w / w) of a chaotropic agent (e.g., guanidine thiocyanate), 2.65%±10% (w / w) of a buffer (e.g., Tris), 0.81%±10% (w / w) of a chelating agent (e.g., disodium EDTA dihydrate), 0.279%±10% (w / w) of a surfactant (e.g., SLS), 17.73%±10% (w / w) of an alcohol (e.g., SDA 3C or a mixture of 95%±10% (v / v) ethanol and 5%±10% (v / v) isopropanol), 0.093%±10% (w / w) mucolytic agent (e.g., N-acetyl-L-cysteine), and / or an appropriate amount of acid (e.g., hydrochloric acid) to pH 8.0 (±10%), with an appropriate amount of carrier (e.g., an aqueous carrier, preferably filtered, purified, distilled, and / or deionized water) to 100%. One embodiment may further include 0.00037%±10% (w / w) visual indicator (e.g., FD&C Blue No. 1) or equivalent (e.g., 0.185%±10% (w / w), 0.2%±10% (w / w) visual indicator concentrate (e.g., in water)). In some embodiments, the amount of each component that is ±10% is further ±9%, preferably ±8%, more preferably ±7%, even more preferably ±6%, even more preferably ±5%, even more preferably ±4%, even more preferably ±3%, even more preferably ±2%, even more preferably ±1% (limited to the amounts stated).

[0011] One or more embodiments may include 20-50% (w / w) chaotropic agent, 0.1-5% (w / w) buffer, 0.05-2.5% (w / w) chelating agent, 0.01-5% (w / w) surfactant, 5-25% (w / w) alcohol, 0.005-0.25% (w / w) mucolytic agent, 0.005-5% (w / w) acid or an appropriate amount of acid to pH 6.5-9.5, and / or 10-60% (w / w) carrier or an appropriate amount of carrier up to 100%. One embodiment may include 0.00005-0.5% (w / w) visual indicator (or 0.01-2.5% (w / w), 0.05-5% (w / w) visual indicator concentrate (e.g., in water)).

[0012] One or more embodiments may be (substantially) devoid of (additional or any) antimicrobial agent(s) (e.g., bactericidal agent(s) and / or bacteriostatic agent(s)) (e.g., other than or otherwise than alcohol(s), chaotropic agent(s), surfactant(s) / detergent(s), and / or mucolytic agent(s)). One or more embodiments may be (substantially) devoid of (additional or any) ribonuclease inhibitor(s) or inhibitor(s) of ribonucleases (e.g., other than or otherwise than chaotropic agent(s). One or more embodiments may be (substantially) devoid of (any) protease(s).

[0013] Some embodiments include a method of stabilizing nucleic acid. The method may include obtaining a biological sample containing nucleic acid and combining the composition of the present disclosure with the biological sample. The method may also include other processing steps well known in the art. One embodiment of the present disclosure includes a method of stabilizing nucleic acid (e.g., human nucleic acid, such as human DNA). One embodiment includes contacting a biological sample containing nucleic acid with the composition of the present disclosure. In one embodiment, the biological sample includes human saliva.

[0014] Some embodiments include a biological sample preservation kit. The kit may include a sample collection device and a nucleic acid preservation composition. The sample collection device may include a solution compartment. The nucleic acid preservation composition may be disposed in the solution compartment. One embodiment of the present disclosure includes a kit that includes a composition of the present disclosure disposed in a portion of a sample collection device.

[0015] Some embodiments include a method for producing the composition of the present disclosure. The method may include combining the components of the present disclosure. The method may also include other manufacturing steps known in the art. One embodiment of the present disclosure includes a method for producing a nucleic acid stabilizing composition. One embodiment includes obtaining a carrier and adding a component or ingredient of the composition of the present disclosure to the carrier.

[0016] Additional features and advantages of exemplary embodiments of the present disclosure will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by the practice of such exemplary embodiments. The features and advantages of such embodiments may be realized and obtained by means of the instruments and combinations particularly pointed out in the appended claims. These and other features will become more fully apparent from the following description and the appended claims, or may be learned by the practice of such exemplary embodiments as set forth hereinafter. [Brief description of the drawings]

[0017] To explain the manner in which the above and other advantages and features of the present disclosure can be obtained, a more particular description of the embodiment briefly described above will be provided by reference to the specific embodiment thereof as illustrated in the accompanying drawings. For better understanding, similar elements are designated by similar reference numerals throughout the figure(s). It being understood that these drawings represent only typical embodiments of the invention and therefore should not be considered as limiting its scope, the invention will be described and explained with additional specificity and detail through the use of the accompanying drawing(s).

[0018] [Figure 1A] 1 is an image of a gel having high molecular weight DNA preserved using a composition according to an embodiment of the present disclosure. [Figure 1B] This is an image of a gel using the Bionexus All Purpose HI-LO DNA Marker. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0019] Before describing various embodiments of the present disclosure in detail, it should be understood that the present disclosure is not limited to the specific parameters and descriptions of specifically illustrated systems, methods, and / or products, which may vary in each embodiment. Thus, although certain embodiments of the present disclosure will be described in detail with reference to specific features (e.g., configurations, parameters, characteristics, steps, components, ingredients, members, elements, parts, and / or portions, etc.), the descriptions are illustrative and are not intended to limit the scope of the present disclosure and / or the claimed invention. In addition, the terms used herein are for the purpose of describing the embodiments and are not necessarily intended to limit the scope of the present disclosure and / or the claimed invention.

[0020] Although the detailed description is divided into paragraphs, the paragraph headings and contents within each paragraph are not intended to be independent descriptions and embodiments. Rather, the contents of each paragraph within the detailed description are intended to be read and understood as a collective whole in which elements of one paragraph may relate to and / or inform other paragraphs. Thus, an embodiment specifically disclosed in one paragraph may also relate to and / or function as additional and / or alternative embodiments in another paragraph having the same and / or similar systems, devices, methods, and / or terminology.

[0021] Brief list of defined terms To aid in understanding the scope and content of the foregoing, as well as the following description and claims, certain selected terms are defined below. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.

[0022] As used herein, the transitional phrase "consisting essentially of" means that the scope of the claim should be interpreted to include the specific materials or steps recited in the claim and which do not "materially affect the basic and novel characteristic(s)" of the claimed invention. See In re Herz, 537 F.2d 549,551-52,190 USPQ461,463 (CCPA 1976) (emphasis in original); see also MPEP § 2111.03. Thus, the term "consisting essentially of" when used in the claims of this disclosure is not intended to be interpreted as equivalent to "comprise."

[0023] As used herein, the term "nucleic acid" refers to naturally occurring or synthetic oligonucleotides or polynucleotides that can hybridize to complementary nucleic acids by Watson-Crick base pairing, whether DNA or RNA or DNA-RNA hybrid single-stranded or double-stranded, sense or antisense. The nucleic acids of the present invention can also include nucleotide analogs (e.g., BrdU, dUTP, 7-deaza-dGTP), and non-phosphodiester internucleoside linkages (e.g., peptide nucleic acid (PNA) or thiodiester linkages). In particular, nucleic acids can include, but are not limited to, DNA, RNA, cDNA, gDNA, ssDNA, dsDNA, or any combination thereof.

[0024] The terms "sample", "biological sample" and the like refer to an animal; a tissue or organ from an animal; a cell (whether within a subject, directly removed from a subject, or from cells maintained in culture or cultured cell lines); a cell lysate (or lysate fraction) or cell extract; a solution containing one or more molecules (e.g., polypeptides or nucleic acids) from cells, cellular material, or viral material; or a solution containing naturally occurring or non-naturally occurring nucleic acid that is or can be assayed as described herein. A sample may also be any bodily fluid or excreta that contains one or more cells, cellular components, or nucleic acid, including but not limited to cellular, nuclear, or cell-free nucleic acid.

[0025] By "body fluid" is meant naturally occurring fluids, including, but not limited to, fluids from animals (e.g., humans or non-human animals), semi-solids, aerated liquids, liquid-gas mixtures, etc. Such body fluids may include, but are not limited to, saliva, phlegm, serum, plasma, blood, urine, mucus, sweat, tears or other ophthalmic fluids, ear fluids, urine (e.g., from blisters or ulcers), gastric juices, feces, pancreatic juices, semen, milk or menstrual products, cerebrospinal fluid, humoral bone marrow, or lymphatic fluid.

[0026] "Sputum" means the mucoid material contained in or discharged from the nasal or oral cavities of a mammal. As used herein, sputum generally includes saliva and discharge from the respiratory tract, including the lungs.

[0027] "Saliva" means the secretions or combination of secretions from any salivary gland, including the parotid, submandibular, and sublingual glands, optionally mixed with secretions from the oral glands.

[0028] By "mucoid" is meant any body fluid that contains mucin.

[0029] By "mucin" is meant any mucoprotein that increases the viscosity of the medium surrounding the cells that secrete it.

[0030] As used herein, with respect to a value, the term "about" means + / - 10% of the stated value or the amount represented thereby. For example, throughout this disclosure, the term "about" is used with respect to a percent concentration or composition of a component or ingredient (e.g., in a mixture such as a fluid or liquid mixture, an aqueous mixture, a solution, etc., optionally or preferably measured as w / w percent, w / v percent, v / v percent, etc.). In such cases, the term "about" and / or the term "+ / - 10%" means and / or includes + / - 10% of the stated numerical value, as opposed to + / - 10 percentage points of the recited percentage. As an example, if 20% (w / w) of a component or ingredient reflects 20 g of the component or ingredient per 100 mL of the total mixture, then the term "about" and / or the term "+ / -10%" means and / or includes the stated range of 18 g to 22 g (i.e., 18% (w / w) to 22% (w / w)) rather than the range of 10% (w / w) to 30% (w / w). Alternatives to so-called "about" values ​​and / or + / -10% include + / -1%, + / -2%, + / -3%, + / -4%, + / -5%, + / -6%, + / -7%, + / -8%, or + / -9% of the stated value, each of which is considered as an appropriate alternative or substitute for the use of the term "about" or + / -10% herein.

[0031] As used herein, the terms "approximately" and "substantially" refer to or mean an amount (or amounts) close to the stated amount (e.g., still performing a desired function or achieving a (desired or expected) result). For example, the terms "approximately" and "substantially" can refer to an amount within or less than 10%, 5%, 1%, 0.1%, 0.01%, or other percentage of the stated amount. As used herein, the term "substantially free" means (1) an undetectable or unquantifiable amount, (2) an amount less than or equal to an amount generally considered by one of ordinary skill in the art to reflect a detectable or quantifiable amount, and / or (3) an amount less than or equal to an amount generally considered by one of ordinary skill in the art to be functional or capable of achieving a (desired or expected) result (e.g., less than 10%, 5%, 1%, 0.1%, 0.01%, or other percentage).

[0032] "Adequate amount" (also referred to as "qualified quantity (qs)" or "qualified quantity (qs)") means a sufficient amount. Thus, "100% of adequate amount," "provided in 100% adequate amount," or "adequate amount to 100%" of a component or ingredient indicates that the component or ingredient is provided or included in an amount sufficient to complete the composition or to bring the total (of all components, whether listed or not) to 100%. However, it should be noted that "100% of adequate amount," "provided in 100% adequate amount," or "adequate amount to 100%" (final) component or ingredient does not indicate that the mixture consists of, consists essentially of, or contains only the component listed or recited immediately before the "qualified amount (qs)" component. In other words, "100% of adequate amount" and similar terms are meant to be open-ended expressions indicating the source of the remainder, whatever the remainder may be.

[0033] By "alcohol" is meant water-miscible organic compounds containing hydroxyl groups, including water-miscible mixtures of hydroxyl-containing organic compounds.

[0034] By "aqueous" is meant a medium or substance that contains 30% or more water (by volume or weight).

[0035] By "aqueous solution" is meant a solution or suspension containing 30% or more water by volume.

[0036] "Denaturant" means a substance that alters the native state of what it is added to.

[0037] "Chaotropic agent" refers to a molecule that exerts chaotropic activity. As will be understood by those skilled in the art, a molecule that exerts chaotropic activity can affect the stability of the native state of other molecules (in solution), mainly macromolecules (proteins, nucleic acids), by disrupting the hydrogen bond network between water molecules, thereby weakening the hydrophobic effect. Thus, a molecule that exerts chaotropic activity can have protein denaturing activity (or can be a protein denaturant).

[0038] "Antimicrobial agent" refers to a substance or group of substances that reduces the growth rate of an organism compared to the growth rate of the organism in its absence. The reduction in the growth rate of the organism can be at least 5%, more preferably at least 10%, even more preferably at least 20%, 50%, or 75%, and most preferably 90% or more. The definition also extends to substances that affect the viability, toxicity, or pathogenicity of an organism. Antimicrobial agents can be natural (e.g., derived from bacteria or other sources), synthetic, or recombinant. Antimicrobial agents can be bacteriostatic, bacteriocidal, or both. An antimicrobial agent is bacteriostatic if it inhibits cell division without affecting the viability of the inhibited cells. An antimicrobial agent is bacteriocidal if it causes cell death. Cell death is generally detected by the absence of cell growth in liquid growth media (e.g., the absence of turbidity) or on solid surfaces (e.g., the absence of colony formation on agar). Those skilled in the art know that a substance or group of substances that is bacteriostatic at a given concentration can become bacteriocidal at a higher concentration. Certain bacteriostatic substances are not bactericidal at any concentration.

[0039] As used herein, "acetylcysteine" or "N-acetylcysteine" (NAC) includes any form of acetylcysteine, including N-acetyl-L-cysteine, N-acetyl-D-cysteine, and racemic N-acetylcysteine ​​or a mixture of (racemic) N-acetyl-L-cysteine ​​and N-acetyl-D-cysteine. Reference to a form of acetylcysteine ​​supports a specific reference to any form of acetylcysteine.

[0040] As used herein, the term "composition" includes articles of manufacture, formulations, and mixtures, as well as apparatus, devices, assemblies, kits, etc. Similarly, the term "method" includes processes, procedures, steps, and the like.

[0041] Various aspects of the present disclosure, including systems, methods, and / or products, may be illustrated with reference to one or more embodiments or implementations that are exemplary in nature. As used herein, the terms "embodiment" and "implementation" mean "serving as an example, instance, or illustration" and should not necessarily be construed as preferred or advantageous over other aspects disclosed herein. Moreover, reference to an "implementation" of the disclosure or invention includes specific reference to one or more embodiments thereof, and vice versa, and is intended to provide illustrative examples without limiting the scope of the invention, which is indicated by the appended claims rather than the description thereof.

[0042] As used herein, a "feature" of the present disclosure or the embodiments disclosed herein refers to a property, component, ingredient, element, member, part, (method) step, or other aspect of the subject matter at hand.

[0043] As used throughout this disclosure, the words "can" and "may" are used in a permissive sense (i.e., meaning having the possibility) rather than a mandatory sense (i.e., meaning must). Additionally, the terms "including," "having," "involving," "containing," "characterized by," variations thereof (e.g., "includes," "has," and "involves," "contains," etc.) and similar terms used herein, including the claims, are intended to be inclusive and / or open ended; illustratively, the word "comprising" and variations thereof (e.g., "comprise" and "comprises" are intended to have the same meaning and do not exclude additional, unrecited elements or method steps.

[0044] As used herein, the word "or" means any one member of a particular list and also includes any combination of members of that list.

[0045] As used herein and in the appended claims, the singular forms "a," "an," and "the" each contemplate, include, and specifically disclose both singular and plural referents unless expressly indicated otherwise. For example, reference to a "protein" contemplates and specifically discloses one, as well as two or more proteins. Similarly, the use of a plural referent does not necessarily require a plurality of such referents, but contemplates, includes, and specifically discloses one, as well as two or more of such referents, unless expressly indicated otherwise.

[0046] It should be noted that an embodiment of the present disclosure may include one or more combinations of two or more features described herein. As used herein, "feature(s)" and similar terms may include, for example, compositions, components, components, elements, members, members, parts, systems, methods, configurations, parameters, properties, and the like. An embodiment may include any of the features, options, and / or possibilities described elsewhere in this disclosure, including other aspects or embodiments of the present disclosure. It should also be noted that each of the foregoing, following, and / or other features described herein represents a separate embodiment of the present disclosure. A feature may also be combined and / or combined with another one or more other features in any suitable combination and / or order, with or without one or more additional features, or performed among them, to form a unique embodiment, each of which is contemplated in the present disclosure. Moreover, such combinations of any two or more of such features represent separate embodiments of the present disclosure. Thus, the present disclosure is not limited to the specific combination of exemplary embodiments detailed herein, and the disclosure of a particular feature in connection with a particular embodiment of the present disclosure should not be construed as limiting the application or inclusion of that feature in that particular embodiment.

[0047] In addition, features described in various embodiments are optional and may not be included in other embodiments of the present disclosure, unless the feature is described as required in a particular embodiment. Furthermore, any feature herein may be combined with any other feature of the same or different embodiments disclosed herein, unless the feature is described as requiring another feature in combination with it. Similarly, any steps recited in any method described herein and / or recited in the claims may be performed in any suitable order and are not necessarily limited to the order described and / or recited, unless otherwise specifically (expressly or implicitly) recited. However, such steps may also be required to be performed in a particular order in certain embodiments of the present disclosure.

[0048] It will also be understood that where more than one value, or range of values ​​(e.g., less than, greater than, at least, and / or up to a particular value, and / or between two recited values) is disclosed or recited, any particular value or range of values ​​within the disclosed values ​​or range of values ​​is likewise specifically disclosed and contemplated herein. Thus, disclosure of an exemplary measurement (e.g., length, width, thickness, etc.) that is about 10 units or less, or between 0 and 10 units, illustratively includes specific disclosure of (i) measurements of 9 units, 5 units, 1 unit, or any other value between 0 and 10 units, including 0 units and / or 10 units; and / or (ii) measurements of 9 units to 1 unit, 8 units to 2 units, 6 units to 4 units, and / or any other value range between 0 and 10 units.

[0049] For ease of understanding, similar references (i.e., similar names of components and / or elements) have been used, where possible, to denote similar elements common to different embodiments of the present disclosure. Similarly, similar components, or components having similar functions, will be provided with similar reference designations, where possible. Certain language will be used herein to describe exemplary embodiments. It will nevertheless be understood that no limitation of the scope of the disclosure is intended thereby. Rather, it will be understood that the language used to describe exemplary embodiments is merely illustrative (unless such language is expressly stated herein as essential) and is not to be construed as limiting the scope of the disclosure.

[0050] Exemplary embodiments The following description of the embodiments includes disclosure related to one or more embodiments of the present disclosure.Therefore, some embodiments may include the features disclosed in the following examples without departing from the scope of the present disclosure.In other words, the features disclosed in the following examples may be included and / or incorporated in any one or more embodiments disclosed herein.

[0051] composition Some embodiments of the present disclosure include compositions. The compositions can provide sputum or saliva as a viable nucleic acid source for purification and analysis. The compositions provide advantageous properties of chemical stabilization of nucleic acids and inhibition of nucleases, including deoxyribonucleases, and microbial growth. Chemical stabilization of nucleic acids in saliva samples can be achieved by using buffers, acids, chelating agents, mucolytic agents, chaotropic agents, detergents, and alcohols.

[0052] The compositions of the present disclosure, when mixed with a biological sample, such as a mucin-containing body fluid, can preserve nucleic acids for extended periods of time at room temperature under ambient conditions. Samples can also be refrigerated, but there is no need to freeze the sample prior to nucleic acid recovery and purification. The properties of certain compositions of the present disclosure are that they (a) chemically stabilize nucleic acids, (b) inhibit nucleases that may be present in saliva, and (c) are compatible with proteolytic enzymes and other reagents used to purify / amplify oligonucleotides or polynucleotides.

[0053] Carrier In at least one embodiment, the composition may include a carrier.Preferably, the carrier may be a liquid carrier or solvent, more preferably an aqueous carrier or solvent, even more preferably water.Most preferably, the carrier may be or include purified, filtered (e.g., 0.2 micron filtered), distilled, and / or deionized water.Thus, the composition may include a carrier.The carrier may be or include water, such as filtered water, purified water, distilled water, or deionized water.

[0054] In some embodiments, the composition may contain a suitable amount of carrier up to 100%. In some embodiments, the composition may contain 10-60% (w / w), preferably 15-55% (w / w), more preferably 20-50% (w / w), even more preferably 25-45% (w / w), even more preferably 28-40% (w / w), even more preferably 30-35% (w / w), even more preferably 31-34% (w / w), even more preferably 32-33% (w / w) (or any value or range of values ​​therebetween) of carrier. Most preferably, the composition may contain (about) 32.602% (w / w) water.

[0055] Chaotropic Agents The composition may include one or more chaotropic agents. In one or more embodiments, the chaotropic agent(s) may be a protein denaturant. In some embodiments, the chaotropic agent may be selected from the group consisting of guanidinium chloride and / or guanidinium thiocyanate. Thus, in at least one embodiment, the composition may include a chaotropic agent. Preferably, the chaotropic agent may be or may include guanidine (or guanidinium) or a suitable salt thereof. More preferably, the chaotropic agent may be or may include guanidinium thiocyanate. In at least one embodiment, the chaotropic agent may be or may include a thiocyanate. In at least one embodiment, the chaotropic agent may be or may include guanidine isothiocyanate, guanidine chloride, guanidine hydrochloride, guanidinium iodide, and the like.

[0056] In some embodiments, the chaotropic agent may be, have, include, or be provided in a dry, solid, powder, anhydrous, and / or granular form. In some embodiments, the chaotropic agent may have a purity of at least, up to, and / or about 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% (as measured by a suitable material assay, such as CoA). In some embodiments, the chaotropic agent may include or be provided in the form of a stock solution (e.g., in water) having any suitable concentration. In some embodiments, the chaotropic agent may have a purity that substantially corresponds to the concentration of the chaotropic agent in the solution (as measured by a suitable material assay, such as CoA).

[0057] In some embodiments, the composition may comprise 20-50% (w / w), preferably 25-49% (w / w), more preferably 30-48% (w / w), even more preferably 35-47% (w / w), even more preferably 40-46% (w / w), even more preferably 42-45% (w / w), even more preferably 43-44% (w / w) (or any value or range of values ​​therebetween) of a chaotropic agent (e.g., guanidine thiocyanate). Most preferably, the composition may comprise (about) 43.92% (w / w) of guanidine thiocyanate. A chaotropic agent (e.g., guanidine thiocyanate) may be included in the composition at about 43.92% (w / w), or in the range of about 35% to about 50% (w / w), preferably about 40% to about 46% (w / w), more preferably about 42% to about 45% (w / w), and even more preferably about 43% to about 44% (w / w).

[0058] Buffer The composition may include one or more buffering agents (or buffers, pH buffers, etc.). Examples of buffering agents include, but are not limited to, tris(hydroxymethyl)aminomethane (also known as Tris; Tris base, 2-amino-2-(hydroxymethyl)-1,3-propanediol, THAM, trometamol) or suitable formulations thereof (e.g., tris(hydroxymethyl)aminomethane hydrochloride or Tris-HCl), Trizma® base (e.g., stock solution of Tris 40% (w / w) in water), HEPES, BES, MOPS, HEPES, TAE, TBE, phosphate buffer, sodium borate buffer, sodium cacodylate buffer, and the like. Preferably, the buffering agent may be or include tris(hydroxymethyl)aminomethane (Tris). More preferably, the buffering agent may be or include Tris-HCl. Most preferably, the buffering agent may be or include Trizma® base.

[0059] In some embodiments, the buffering agent may be, have, include, or be provided in a dry, solid, powdered, anhydrous, and / or granular form. In some embodiments, the buffering agent may have a purity of at least, up to, and / or about 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% (as measured by a suitable material assay such as CoA). In some embodiments, the buffering agent may include or be provided in the form of a stock solution (e.g., in water) having any suitable concentration (e.g., a stock solution of Tris-40% (w / w) in water). In some embodiments, the buffering agent may have a purity that substantially corresponds to the concentration of the buffering agent in solution (as measured by a suitable material assay such as CoA).

[0060] The buffer may be present in the composition at about 2.65% (w / w), or in the range of about 0.1% to about 5% (w / w), preferably about 0.5% to about 4.5% (w / w), more preferably about 0.75% to about 4% (w / w), even more preferably about 1% to about 3.5% (w / w), even more preferably about 1.5% to about 3.25% (w / w), even more preferably about 2% to about 3% (w / w), and even more preferably about 2.5% to about 2.8% (w / w). In some embodiments, the composition may comprise 1-5% (w / w), preferably 1.25-4.5% (w / w), more preferably 1.5-4% (w / w), even more preferably 1.75-3.75% (w / w), even more preferably 2-3.5% (w / w), even more preferably 2.25-3% (w / w), even more preferably 2.5-2.75% (w / w) (or any value or range of values ​​therebetween) of a buffering agent (e.g., Tris). Most preferably, the composition may comprise (about) 2.65% (w / w) Tris.

[0061] Chelating Agents In at least one embodiment, the composition may include a chelating agent (or chelating agent). Preferably, the chelating agent may be or may include ethylenediaminetetraacetic acid (EDTA) or a suitable salt and / or hydrate thereof. More preferably, the chelating agent may be or may include or may be provided as EDTA disodium salt. Even more preferably, the chelating agent may be or may include or may be provided as EDTA disodium (salt) dihydrate. In at least one embodiment, the chelating agent may be or may include ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA), nitrilotriacetic acid (NTA), ethylenediamine (or 1,2-diaminoethane), and the like. In some embodiments, the chelating agent includes, contains, or is provided with a counterion (e.g., sodium). In at least one embodiment, the chelating agent includes, contains, or is provided as a hydrate (e.g., dihydrate).

[0062] The composition may include one or more chelating agents. The chelating agent of the composition may be selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), cyclohexanediaminetetraacetic acid (CDTA), diethylenetriaminepentaacetic acid (DTPA), tetraazacyclododecanetetraacetic acid (DOTA), tetraazacyclotetradecanetetraacetic acid (TETA), desferrioximine, nitrilotriacetic acid (NTA), ethylenediamine (or 1,2-diaminoethane), or their respective chelating analogs, salts, and / or hydrates. Preferably, the chelating agent may be or may include EDTA (e.g., as EDTA disodium salt, preferably EDTA disodium (salt) dihydrate). In some embodiments, the chelating agent includes, contains, or is provided with a counterion (e.g., sodium). In at least one embodiment, the chelating agent includes, contains, or is provided as a hydrate (e.g., dihydrate).

[0063] In some embodiments, the chelating agent may be, have, include, or be provided in a dry, solid, powder, anhydrous, and / or granular form. In some embodiments, the chelating agent may have a purity of at least, up to, and / or about 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% (as measured by a suitable material assay, such as CoA). In some embodiments, the chelating agent may include or be provided in the form of a stock solution (e.g., in water) having any suitable concentration. In some embodiments, the chelating agent may have a purity that substantially corresponds to the concentration of the chelating agent in the solution (as measured by a suitable material assay, such as CoA).

[0064] The chelating agent (e.g., EDTA) may be included in the composition at about 0.81% (w / w), or in the range of about 0.05% to about 2.5% (w / w), preferably about 0.1% to about 2% (w / w), more preferably about 0.5% to about 1% (w / w), and even more preferably about 0.75% to about 0.9% (w / w). In some embodiments, the composition may include 0.05 to 2.5% (w / w), preferably 0.1 to 2.25% (w / w), more preferably 0.25 to 2% (w / w), even more preferably 0.5 to 1.75% (w / w), even more preferably 0.6 to 1.5% (w / w), even more preferably 0.7 to 1.25% (w / w), and even more preferably 0.75 to 1% (w / w) (or any value or range of values ​​therebetween) of the chelating agent (e.g., EDTA). Most preferably, the composition may contain (about) 0.81% (w / w) EDTA or disodium EDTA (salt) dihydrate.

[0065] Surfactants In at least one embodiment, the composition may comprise a surfactant or detergent.Preferably, the surfactant may be or comprise lauroyl sarcosinate.More preferably, the surfactant may be or comprise sodium lauroyl sarcosinate (SLS). In at least one embodiment, the surfactant may be or may include one or more members selected from the group consisting of sodium dodecyl sulfate (SDS), polysorbates (Tween™), lauryl dimethylamine oxide, cetyltrimethylammonium bromide (CTAB), polyethoxylated alcohols, polyoxyethylene, sorbitan, octoxynol (Triton X100™), N,N-dimethyldodecylamine-N-oxide, hexadecyltrimethylammonium bromide (HTAB), polyoxyl 10 lauryl ether, bile salts (sodium deoxycholate, sodium cholate), polyoxyl castor oil (Cremophor™), nonylphenol ethoxylate (Tergitol™), cyclodextrin, lecithin, methylbenzethonium chloride (Hyamine™), and the like. The composition may include surfactants or detergents such as urea, perchlorate, sodium dodecyl sulfate (SDS), and / or sodium lauroyl sarcosinate (SLS), preferably sodium lauroyl sarcosinate (SLS). In some embodiments, SLS may be preferred over SDS or other (less soluble) surfactants.

[0066] In some embodiments, the surfactant may be, have, include, or be provided in a dry, solid, powder, anhydrous, and / or granular form. In some embodiments, the surfactant may have a purity of at least, up to, and / or about 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% (measured by a suitable material assay such as CoA). In some embodiments, the surfactant may include or be provided in the form of a stock solution (e.g., in water) having any suitable concentration (e.g., about 10%, 15%, 20%, 25%, 28%, 29%, 30%, 32%, 35%, 40%, or 45% (w / w) of aqueous solution (e.g., in water). In some embodiments, the surfactant may have a purity that substantially corresponds to the concentration of the surfactant in solution (e.g., about 30% (w / w)) (as measured by an appropriate material assay such as CoA).

[0067] In some embodiments, the surfactant (e.g., SLS) may be included in the composition at about 0.279% (w / w). In some embodiments, the surfactant may be included in the composition at about 0.01% to about 5% (w / w), preferably about 0.025% to about 2.5% (w / w), more preferably about 0.05% to about 2% (w / w), even more preferably about 0.075% to about 1.5% (w / w), even more preferably about 0.1% to about 1% (w / w), even more preferably about 0.15% to about 0.5% (w / w), even more preferably about 0.2% to about 0.4% (w / w), even more preferably about 0.25% to about 0.3% (w / w). Some embodiments include 0.01%-5% (w / w), preferably 0.025%-2.5% (w / w), more preferably 0.05%-2% (w / w), even more preferably 0.075%-1.5% (w / w), even more preferably 0.1%-1% (w / w), even more preferably 0.15%-0.5% (w / w), even more preferably 0.2%-0.4% (w / w), even more preferably 0.25%-0.3% (w / w), and most preferably 0.279% (w / w). In at least one embodiment, the surfactant (e.g., SLS) may be included in the composition at about 0.93% (w / w) of a stock solution (aqueous solution) of 30%, or its equivalent.

[0068] alcohol In at least one embodiment, the composition may include alcohol. Preferably, the alcohol may be or may include ethanol. More preferably, the alcohol may be or may include a mixture of ethanol and one or more additional chemicals or components. In at least one embodiment, the one or more additional chemicals or components may be or may include isopropanol. Even more preferably, the alcohol may be or may include a mixture of ethanol and isopropanol. In at least one embodiment, the one or more additional chemicals or components may be or may include methanol, propanol, butanol, isobutanol, and the like. In at least one embodiment, the alcohol may be or may include specially denatured alcohol (SDA). More preferably, the alcohol may be or may include SDA 3C, known to those skilled in the art to include a mixture of about 95% (v / v) ethanol and about 5% (v / v) isopropanol. The composition may comprise an alcohol such as ethanol, methanol, propanol, and / or isopropanol, preferably a mixture of specially denatured alcohol (SDA) or ethanol with another alcohol such as methanol, n-propanol, isopropanol, n-butanol, trifluoroethanol, phenol, or 2,6-di-tert-butyl-4-methylphenol, more preferably a mixture of ethanol and isopropanol, even more preferably a mixture of ethanol and isopropanol with one or more additional chemicals or components.

[0069] In some embodiments, the surfactant may be, have, include, or be provided in dry, solid, powder, anhydrous, and / or granular form. In some embodiments, the alcohol may be, have, include, or be provided in the form of a liquid, aqueous, and / or solution. In some embodiments, the alcohol may be included or provided in the form of a stock solution (e.g., in water) having any suitable concentration of alcohol (e.g., in water). In some embodiments, the alcohol may be substantially pure or may be a mixture of substantially pure alcohol. In some embodiments, the alcohol may have a purity of at least, up to, and / or about 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% (or pure ethyl alcohol, 200 proof) (as measured by an appropriate material assay such as CoA).

[0070] In some embodiments, the alcohol may be or may comprise a mixture or stock solution of or containing about 95% (v / v) ethanol and about 5% (v / v) isopropanol. In some embodiments, the alcohol may be or may comprise a mixture or stock solution of or containing 90-99% (v / v) ethanol and about 1-10% (v / v) isopropanol. In certain embodiments, the alcohol may comprise a mixture of 50-99% (v / v) ethanol and 1-50% (v / v) isopropanol. More preferably, the alcohol may comprise a mixture of 60-98% (v / v) ethanol and 2-40% (v / v) isopropanol. Even more preferably, the alcohol may comprise a mixture of 75-97% (v / v) ethanol and 3-25% (v / v) isopropanol. Even more preferably, the alcohol may comprise a mixture of 80-96% (v / v) ethanol and 4-20% (v / v) isopropanol. Even more preferably, the alcohol may comprise a mixture of 85-95% (v / v) ethanol and 5-15% (v / v) isopropanol. Even more preferably, the alcohol may comprise a mixture of 90-95% (v / v) ethanol and 5-10% (v / v) isopropanol. Even more preferably, the alcohol may comprise a mixture of 92-95% (v / v) ethanol and 5-8% (v / v) isopropanol. Even more preferably, the alcohol may comprise a mixture of 95% (v / v) ethanol and 5% (v / v) isopropanol. Most preferably, the alcohol may be or comprise SDA 3C.

[0071] Alcohol (e.g., SDA 3C) may be included in the composition at about 17.73% (w / w), or in the range of about 10% to about 25% (w / w), preferably about 12% to about 22% (w / w), more preferably about 15% to about 20% (w / w), even more preferably about 16% to about 19% (w / w), and even more preferably about 17% to about 18% (w / w). In some embodiments, the amount of alcohol included in the composition may be less than typical, traditional, or existing nucleic acid preservation solutions (e.g., less than about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60%) (e.g., making the composition more amendable for shipping or transportation). In some embodiments, the composition may comprise 5-25% (w / w), preferably 10-22% (w / w), more preferably 12-20% (w / w), even more preferably 15-19% (w / w), even more preferably 16-18.5% (w / w), even more preferably 17-18.25% (w / w), even more preferably 17.5-18% (w / w) (or any value or range of values ​​therebetween) alcohol.

[0072] Preferably, the alcohol comprises a mixture of ethanol and one or more additional chemicals or components such as isopropanol, more preferably a mixture of about 95% (v / v) ethanol and about 5% (v / v) isopropanol. Even more preferably, the alcohol is specially denatured alcohol (SDA), even more preferably SDA 3C (i.e., a mixture of ∼95% (v / v) ethanol and ∼5% (v / v) isopropanol). Most preferably, the composition may comprise (approximately) 17.73% (w / w) SDA 3C. In some embodiments, alcohol (e.g., SDA 3C) may be included in the composition at about 16.84% (w / w) ethanol, or in the range of about 10% to about 25% (w / w), preferably about 12% to about 22% (w / w), more preferably about 15% to about 20% (w / w), even more preferably about 16% to about 18% (w / w), even more preferably about 16.5% to about 17% (w / w) ethanol, and about 0.89% (w / w) isopropanol, or in the range of about 0.05% to about 2.5% (w / w), preferably about 0.1% to about 2% (w / w), more preferably about 0.5% to about 1.5% (w / w), even more preferably about 0.75% to about 1.25% (w / w), even more preferably about 0.8% to about 1% (w / w) isopropanol.

[0073] In some embodiments, the composition may contain less alcohol (e.g., less than about 50%) than typical, traditional, or existing nucleic acid preservation solutions (e.g., making the composition more amendable for shipping or transport).

[0074] acid In at least one embodiment, the composition may include an acid. Preferably, the acid may be or include hydrochloric acid (HCl). In at least one embodiment, the acid may be or include hydrobromic acid (HBr), perchloric acid (HClO4), nitric acid (HNO3), or sulfuric acid (H2SO4). In at least one embodiment, the acid may be or include carbonic acid (H2CO3) or acetic acid (CH3COOH). In at least one embodiment, the acid may be or include phosphoric acid (H3PO4), boric acid (H3BO3), or emerald safe acid (ESA), etc.

[0075] In some embodiments, the acid may be, have, include, or be provided in a dry, solid, powder, anhydrous, and / or granular form. In some embodiments, the acid may have a purity of at least, up to, and / or about 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% (as measured by a suitable material assay such as CoA). In some embodiments, the acid may include or be provided in the form of a stock solution (e.g., in water) having any suitable concentration (e.g., about 10%, 15%, 20%, 25%, 30%, 32%, 35%, 37%, 38%, 40%, or 45% (w / w) of aqueous solution (e.g., in water). In some embodiments, the acid can have a purity that substantially corresponds to the concentration of the acid in solution (eg, about 37% (w / w)) (as measured by a suitable material assay such as CoA).

[0076] In some embodiments, the composition may contain an amount of acid (e.g., hydrochloric acid) to provide a pH of about 8.0, or up to pH 7.5-9.5, pH 6.5-9.5, pH 7-9, pH 7.2-8.8, pH 7.4-8.6, pH 7.5-8.5, pH 7.6-8.4, or pH 7.8-8.2 (or any value or range of values ​​therebetween). In some embodiments, the pH of the composition may be greater than about 5 to less than about 12, preferably within a pH range of about 6 to about 11, more preferably within a pH range of about 6 to about 10, even more preferably within a pH range of about 7 to about 9, even more preferably within a pH range of about 7.5 to about 8.5, and most preferably a pH of about 8.0.

[0077] In some embodiments, the acid (e.g., hydrochloric acid) may be included in the composition at about 0.4% (w / w), or in the range of about 0.01% to about 5% (w / w), preferably about 0.025% to about 2.5% (w / w), more preferably about 0.05% to about 2% (w / w), more preferably about 0.1% to about 1.5% (w / w), more preferably about 0.25% to about 1% (w / w), more preferably about 0.5% to about 0.75% (w / w), more preferably about 0.3% to about 0.5% (w / w). In some embodiments, the composition may include 0.005 to 5%, preferably 0.01 to 2.5%, more preferably 0.025 to 1.5%, even more preferably 0.05 to 1%, even more preferably 0.1 to 0.75%, even more preferably 0.25 to 0.5% acid (e.g., hydrochloric acid). In at least one embodiment, an acid (e.g., hydrochloric acid) may be included in the composition at about 1.08% (w / w) of 37% (w / w) or a stock solution (aqueous solution) of 12M, or its equivalent. Most preferably, the composition may contain (about) 1.08% (w / w) of 37% (w / w) hydrochloric acid, or its equivalent, or an amount of hydrochloric acid up to a pH of (about) 8.0.

[0078] Without being bound by any theory, different acids have different "strengths" or amounts of protons (H +It should be noted, and one of skill in the art would understand, that a strong acid has the ability or tendency to lose ions (H2O) to form a strong acid. A strong acid is one that will completely ionize (dissociate) in solution (if there is sufficient solvent). For example, in water, 1 mole of the strong acid HA will dissolve and 1 mole of H + (Hydronium ion H3O + (or as larger aggregates) and 1 mole of conjugate base A - Essentially no unionized acid HA remains. Some examples of strong acids are hydrochloric acid (HCl), hydroiodic acid (HI), hydrobromic acid (HBr), perchloric acid (HClO4), nitric acid (HNO3) and sulfuric acid (H2SO4). In aqueous solution, each of these is essentially 100% ionized. In contrast, weak acids only partially dissociate. Examples in water include carbonic acid (H2CO3) and acetic acid (CH3COOH). At equilibrium, both the acid and the conjugate base are present in solution. Stronger acids have larger acid dissociation constants (Ka) and smaller logarithmic constants (pKa=-logKa) than weaker acids. Stronger acids are more likely to lose the proton H+. Two important factors that contribute to the ease of deprotonation are the polarity of the HA bond and the size of atom A, which determines the strength of the HA bond. Acid strength also depends on the stability of the conjugate base.

[0079] In light of the above, the amount (w / w) of each acid required to bring the pH of the composition to a desired level will vary. For example, 1.08% (w / w) of 37% (w / w) hydrochloric acid (in water) may be sufficient to bring certain embodiments of the present disclosure to a pH of (about) 8.0, while 1.08% (w / w) of 37% (w / w) acetic acid (in water) may be too weak to bring the same embodiment to a pH of (about) 8.0, 1.08% (w / w) of 37% (w / w) sulfuric acid (in water) may be too strong to bring the embodiment to a pH of (about) 8.0, and 1.08% (w / w) of 37% (w / w) nitric acid (in water) may oxidize alcohol, etc. Without being bound by any theory, even those skilled in the art may not be able to determine which acid is suitable for one or more embodiments of the present disclosure through further experimentation.

[0080] Mucolytic agents In at least one embodiment, the composition may include a mucolytic agent. In one or more embodiments, the mucolytic agent may be or include a reducing agent. Preferably, the mucolytic agent may be or include acetylcysteine ​​(i.e., N-acetylcysteine ​​(NAC), which includes N-acetyl-L-cysteine, N-acetyl-D-cysteine, and racemic N-acetylcysteine, or a (racemic) mixture of N-acetyl-L-cysteine ​​and N-acetyl-D-cysteine). More preferably, the mucolytic agent may be or include N-acetyl-L-cysteine. In at least one embodiment, the mucolytic agent may be or include N-acetylcysteine ​​(N-acetyl-L-cysteine), ascorbic acid, dithionite, erythorbate, cysteine, glutathione, dithiothreitol, 2-mercaptoethanol, dierythritol, resin-bound thiols, resin-bound phosphines, vitamin E, and / or trolox, or salts thereof, sodium citrate, potassium citrate, potassium iodide, ammonium chloride, guaiphenesin (or guaifenesin), tolu balsam, vasaca, ambroxol, carbocysteine, erdosteine, mecysteine, dornase alfa, etc. The composition may include one or more mucolytic agents. Preferably, the mucolytic agent is ascorbic acid, erythorbate, N-acetylcysteine, dithiothreitol, or 2-mercaptoethanol, and most preferably, the mucolytic agent is N-acetylcysteine.

[0081] In one or more embodiments, the composition does not contain ascorbic acid, dithionite, erythorbate, dithiothreitol, 2-mercaptoethanol, dierythritol, resin-bound thiols, resin-bound phosphines, vitamin E, trolox, and / or salts thereof. At least one embodiment is (substantially) free of ascorbic acid, dithionite, erythorbate, dithiothreitol, 2-mercaptoethanol, dierythritol, resin-bound thiols, resin-bound phosphines, vitamin E, trolox, and / or salts thereof. At least one embodiment is (substantially) free of mucolytic agents other than N-acetyl-L-cysteine.

[0082] In some embodiments, the mucolytic agent may be, have, include, or be provided in a dry, solid, powder, anhydrous, and / or granular form. In some embodiments, the mucolytic agent may have a purity of at least, up to, and / or about 90%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% (as measured by a suitable material assay, such as CoA). In some embodiments, the mucolytic agent may include or be provided in the form of a stock solution (e.g., in water) having any suitable concentration. In some embodiments, the mucolytic agent may have a purity that substantially corresponds to the concentration of the mucolytic agent in solution (as measured by a suitable material assay, such as CoA).

[0083] A mucolytic agent (e.g., N-acetylcysteine) may be included in the composition at about 0.093% (w / w), or in the range of about 0.01% to about 0.5% (w / w), preferably about 0.025% to about 0.25% (w / w), more preferably about 0.05% to about 0.2% (w / w), even more preferably about 0.075% to about 0.15% (w / w), and even more preferably about 0.08% to about 0.1% (w / w).

[0084] In some embodiments, the composition may comprise 0.005-0.25% (w / w), preferably 0.005-0.2% (w / w), more preferably 0.01-0.2% (w / w), even more preferably 0.025-0.175% (w / w), even more preferably 0.05-0.165% (w / w), even more preferably 0.075-0.15% (w / w), even more preferably 0.08-0.125% (w / w), even more preferably 0.09-0.1% (w / w) (or any value or range of values ​​therebetween) of a mucolytic agent (e.g., N-acetyl-L-cysteine). Most preferably, the composition may comprise (about) 0.093% (w / w) N-acetyl-L-cysteine.

[0085] Visual Indicators At least one embodiment may include a visual indicator. Preferably, the visual indicator may be or may include a colorant. More preferably, the visual indicator may be or may include a dye or a colored dye. Even more preferably, the visual indicator may be or may include a blue dye. Most preferably, the visual indicator may be or may include FD&C Blue No. 1. The composition may include a visual indicator, preferably a colorant, more preferably a colored dye, even more preferably a blue dye, even more preferably FD&C Blue No. 1.

[0086] In some embodiments, the visual indicator may be, have, include, or be provided in a dry, solid, powdered, anhydrous, and / or granular form. In some embodiments, the visual indicator may have a purity of at least, up to, and / or about 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8%, or 99.9% (as measured by a suitable material assay, such as CoA). In some embodiments, the visual indicator may include or be provided in the form of a stock solution (e.g., in water) having any suitable concentration (e.g., about 0.01%, 0.05%, 0.075%, 0.1%, 0.125%, 0.15%, 0.175%, 0.2%, 0.25%, 0.3%, or 0.5% (w / w) in aqueous solution (e.g., in water). In some embodiments, the stock solution may be made using dry, solid, powdered, anhydrous, and / or granular materials. In some embodiments, the visual indicator may have a purity substantially equivalent to the concentration of acid in the solution (e.g., about 0.2% (w / w)) (measured by a suitable material assay such as CoA).

[0087] The visual indicator (e.g., FD&C Blue No. 1) may be included in the composition in any visually relevant amount, such as about 0.00037% (w / w), or in the range of about 0.00005% to about 0.001% (w / w), preferably about 0.0001% to about 0.00075% (w / w), more preferably about 0.0002% to about 0.0005% (w / w), even more preferably about 0.0003% to about 0.0004% (w / w). In some embodiments, the composition may include a visible (visually relevant) amount of a visual indicator, preferably a colorant, more preferably a color dye, even more preferably a blue dye, even more preferably FD&C Blue No. 1. Most preferably, the composition may include (about) 0.00037% (w / w) of FD&C Blue No. 1.

[0088] In at least one embodiment, the visual indicator (e.g., FD&C Blue No. 1) can be added to the composition as a concentrate. In some embodiments, the concentrate can be an aqueous or water-based concentrate. In some embodiments, the composition can include 0.01-2.5% (w / w) of a visual indicator concentrate of 0.01-5% (w / w) (in water). Preferably, the composition can include 0.05-1% (w / w) of a visual indicator concentrate of 0.05-1% (w / w) (in water). More preferably, the composition can include 0.075-0.5% (w / w) of a visual indicator concentrate of 0.075-0.5% (w / w) (in water). Even more preferably, the composition can include 0.1-0.25% (w / w) of a visual indicator concentrate of 0.1-0.25% (w / w) (in water). Even more preferably, the composition may comprise (about) 0.185% (w / w) of a visual indicator concentrate of (about) 0.2% (w / w) (in water). In at least one embodiment, the visual indicator (e.g., FD&C Blue No. 1) may be included in the composition at about 0.185% (w / w) of a 0.2% stock solution (aqueous solution), or its equivalent. Most preferably, the composition may comprise (about) 0.185% (w / w) of a FD&C Blue No. 1 concentrate of (about) 0.2% (w / w) (in water).

[0089] Antibacterial agents In some embodiments, the composition may include an antimicrobial agent. In some embodiments, one or more of the aforementioned components may exhibit antimicrobial activity. For example, in some embodiments, the alcohol, chaotropic agent, surfactant, and / or mucolytic agent may be antimicrobial or may exhibit antimicrobial activity. Thus, certain embodiments need not include a separate antimicrobial agent (e.g., a bactericidal and / or bacteriostatic agent). In one or more embodiments, the antimicrobial properties of the alcohol (e.g., SDA 3C) persist even at lower concentrations (e.g., about 17.73% (w / w), or 5-25% (w / w), 10-22% (w / w), 10-20% (w / w), 15-19% (w / w), 16-18.5% (w / w), 17-18.25% (w / w), or 17.5-18% (w / w) (or any value or range of values ​​therebetween)) than the alcohol is provided in the embodiment(s) of the present disclosure.

[0090] Ribonuclease inhibitors Some embodiments include ribonuclease inhibitors or inhibitors of ribonucleases, such as heparin, heparan sulfate, oligo(vinyl sulfonic acid), poly(vinyl sulfonic acid), oligo(vinyl phosphonic acid), and poly(vinyl sulfonic acid), or salts thereof. In certain (e.g., preferred) embodiments, the composition does not include ribonuclease inhibitors or inhibitors of ribonucleases, or is (substantially) free of one or more (e.g., any) ribonuclease inhibitors or inhibitors of ribonucleases (e.g., other than chaotropic agents such as guanidine thiocyanate, which may have endogenous RNAse inhibitory activity). Thus, at least one embodiment is (substantially) free of one or more (e.g., any) ribonuclease inhibitors or inhibitors of ribonucleases. One or more embodiments are (substantially) free of ribonuclease inhibitors or inhibitors of ribonucleases (e.g., other than chaotropic agents such as guanidine thiocyanate).

[0091] Proteases Some embodiments include a protease. In certain (e.g., preferred) embodiments, the composition does not include a protease or is (substantially) free of one or more (e.g., any) proteases. Thus, at least one embodiment is (substantially) free of one or more (any) proteases. Without being bound by any theory, a protease (or proteolytic enzyme, peptidase, or proteinase) is a type of enzyme that cleaves one or more peptide bonds by hydrolysis, thereby converting a protein into smaller protein fragments (or peptides) or individual protein subunits (or amino acids).

[0092] Protein Denaturants Some embodiments include one or more protein denaturants. For example, in at least one embodiment, (i) the chaotropic agent may be, comprise, or function as a protein denaturant (or denatures proteins or has or exhibits protein denaturing activity). In at least one embodiment, (ii) the detergent / detergent may be, comprise, or function as a protein denaturant (or denatures proteins or has or exhibits protein denaturing activity). In at least one embodiment, (iii) the alcohol may be, comprise, or function as a protein denaturant (or denatures proteins or has or exhibits protein denaturing activity). In at least one embodiment, (iv) the mucolytic agent may be, comprise, or function as a protein denaturant (or denatures proteins or has or exhibits protein denaturing activity), such as when the protein(s) contain accessible disulfide bonds or crosslinks. In some embodiments, two or more of (i) the chaotropic agent, (ii) the detergent / detergent, (iii) the alcohol, and (iv) the mucolytic agent may be, comprise, or function as a protein denaturant (or denature a protein or have or exhibit protein denaturing activity). In some embodiments, each or all of (i) the chaotropic agent, (ii) the detergent / detergent, (iii) the alcohol, and (iv) the mucolytic agent may be, comprise, or function as a protein denaturant (or denature a protein or have or exhibit protein denaturing activity).

[0093] Without being bound by any theory, the protein denaturing activity of one or more of the aforementioned components or ingredients may be concentration and / or time dependent.

[0094] compound The present disclosure includes a nucleic acid preservation composition (or formulation) that includes an aqueous carrier, a chaotropic agent, a buffer, a chelating agent, a surfactant, an alcohol, an acid, and a mucolytic agent. One embodiment further includes an optional visual indicator. An embodiment may include 20-50% (w / w) chaotropic agent, 1-5% (w / w) buffer, 0.05-2.5% (w / w) chelating agent, 0.05-2.5% (w / w) surfactant, 5-25% (w / w) alcohol, 0.005-0.25% (w / w) mucolytic agent, an acid in an amount suitable for pH 6.5-9.5, and a carrier in an amount suitable for up to 100%. An embodiment may further include 0.005-2.5% (w / w) visual indicator.

[0095] In at least one embodiment, the composition comprises about 43.92% (w / w) chaotropic agent, about 2.65% (w / w) buffering agent, about 0.81% (w / w) chelating agent, about 0.279% (w / w) surfactant, about 17.73% (w / w) alcohol, about 0.093% (w / w) mucolytic agent, an acid in an amount sufficient to bring the pH to about 8.0 (e.g., about 1.08% of a 37% acid solution, or its equivalent), and a carrier in an amount sufficient to bring the pH to about 100%. The composition may comprise about 0.00037% (w / w) visual indicator.

[0096] In some embodiments, the carrier may be or include an aqueous carrier such as water, preferably filtered, purified, distilled, and / or deionized water. In some embodiments, the chaotropic agent may be or include guanidine and / or thiocyanate, preferably guanidine thiocyanate. In some embodiments, the buffer may be or include tris(hydroxymethyl)aminomethane (Tris), preferably Tris-HCl, more preferably Trizma Base®. In some embodiments, the chelating agent may be or include ethylenediaminetetraacetic acid (EDTA), preferably EDTA disodium (salt) dihydrate. In some embodiments, the surfactant may be or include sodium lauroyl sarcosinate (SLS). In some embodiments, the alcohol may be or include specially denatured alcohol (SDA) or a mixture of ethanol and isopropanol, preferably a mixture of about 95% (v / v) ethanol and about 5% (v / v) isopropanol, or SDA 3C. In some embodiments, the acid can be or include hydrochloric acid, hi some embodiments, the mucolytic agent can be or include N-acetyl-L-cysteine.

[0097] One embodiment of the present disclosure comprises a nucleic acid stabilizing and / or preserving composition comprising about 43.92% (w / w) of a chaotropic agent (e.g., guanidine thiocyanate), about 2.65% (w / w) of a buffering agent (e.g., Tris), about 0.81% (w / w) of a chelating agent (e.g., EDTA or disodium EDTA (salt) dihydrate), about 0.279% (w / w) of a detergent (e.g., SLS), about 17.73% (w / w) of an alcohol (e.g., SDA 3C), about 0.093% (w / w) of a mucolytic agent (e.g., N-acetyl-L-cysteine), a suitable amount of acid (e.g., hydrochloric acid) to a pH of about 8.0, and / or a suitable amount of a carrier (e.g., an aqueous carrier comprising filtered, purified, distilled, and / or deionized water) up to 100%. One embodiment may further comprise about 0.00037% (w / w) of a visual indicator (e.g., FD&C Blue No. 1).

[0098] One embodiment of the present disclosure comprises 43.92%±10% (w / w) of a chaotropic agent (e.g., guanidine thiocyanate), 2.65%±10% (w / w) of a buffer (e.g., Tris), 0.81%±10% (w / w) of a chelating agent (e.g., disodium EDTA dihydrate), 0.279%±10% (w / w) of a surfactant (e.g., SLS), 17.73%±10% (w / w) of an alcohol (e.g., SDA 3C or a mixture of 95%±10% (v / v) ethanol and 5%±10% (v / v) isopropanol), 0.093%±10% (w / w) mucolytic agent (e.g., N-acetyl-L-cysteine), and / or an acid (e.g., hydrochloric acid) in an amount appropriate for pH 8.0 (±10%), together with an appropriate carrier (e.g., an aqueous carrier, preferably filtered, purified, distilled, and / or deionized water) in an amount appropriate for up to 100%. One embodiment further comprises 0.00037%±10% (w / w) visual indicator (e.g., FD&C Blue No. 1) or equivalent (e.g., 0.185%±10% (w / w), 0.2%±10% (w / w) visual indicator concentrate (e.g., in water)). In one embodiment, the amount of each component that is ±10% is further ±9%, preferably ±8%, more preferably ±7%, even more preferably ±6%, even more preferably ±5%, even more preferably ±4%, even more preferably ±3%, even more preferably ±2%, even more preferably ±1% (limited to the amounts stated).

[0099] In at least one embodiment, the composition comprises about 43.92% (w / w) guanidine thiocyanate, about 2.65% (w / w) Tris, about 0.81% (w / w) EDTA or disodium EDTA (salt) dihydrate, about 0.279% (w / w) SLS, about 17.73% (w / w) SDA 3C, about 0.093% (w / w) N-acetyl-L-cysteine, about 1.08% (w / w) 37% hydrochloric acid, or its equivalent, or an appropriate amount of hydrochloric acid up to a pH of about 8.0, and an appropriate amount of water up to 100% (w / w). The composition may include about 0.00037% (w / w) FD&C Blue No. 1 (or 0.185% (w / w) of a 0.2% (w / w) concentrate (in water)), and about 32.602% (w / w) water.

[0100] In some embodiments, the composition may be substantially free or devoid of microbial (e.g., bacterial, fungal, and / or viral) contamination. In some embodiments, the composition may have no more than (about) 100 cfu / g of bacterial or bacterial contamination. In some embodiments, the composition may have no more than (about) 99, 98, 97, 96, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, or 5 cfu / g of bacterial or bacterial contamination. In some embodiments, the composition may have no more than (about) 100 cfu / g of fungal (or fungi such as yeast and / or mold) or fungal contamination. In some embodiments, the composition may have no more than (about) 99, 98, 97, 96, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50, 45, 40, 35, 30, 25, 20, 15, 10, or 5 cfu / g of fungi (or fungi such as yeasts and / or molds) or fungal contamination. As used herein, "cfu / g" refers to colony forming units (of one or more microorganisms) per gram (of the (final and / or liquid) composition).

[0101] Exemplary embodiments of the present disclosure are presented below in Table 1. Table 1 describes the components of the exemplary compositions, as well as the uses, functions, and / or activities of the components.

[0102] [Table 1]

[0103] Table 1.1 provides another exemplary formulation for the composition of the present disclosure.

[0104] [Table 2]

[0105] Further features of the present disclosure can be seen in U.S. Pat. No. 7,482,116, which is incorporated herein by reference in its entirety.

[0106] kit Some embodiments include a kit, such as a biological sample preservation kit. Specifically, in one or more embodiments, the composition of the present invention may be incorporated into a kit. The kit may include, for example, a composition disclosed and / or described herein, as well as a sample collection device. In at least one embodiment, the composition may be disposed in a portion of the sample collection device. An exemplary sample collection device may include a container or vial (e.g., a tube) having a sample collection portion. For example, the container may include an outer wall that at least partially surrounds an internal compartment. The internal compartment may contain a composition to which the biological sample may be added. Alternatively, the sample may be added to the compartment and the composition may be added to the sample after collection. For example, the device may include a composition dispenser for adding the composition to the compartment before or after sample collection. In at least one embodiment, the dispenser may include a cap for closing or sealing an opening of the device. The opening may be open to or in fluid communication with the compartment. The cap may have a compartment for holding the composition until the composition is added to the compartment of the container.

[0107] Some embodiments may include a kit that includes a biological sample collection device (or container) and a composition of the present disclosure. In at least one embodiment, the composition may be disposed in a portion of the device. For example, in some embodiments, the composition may be disposed in a portion of the cap or lid of the device. The collection device (or container) may be configured to contain a biological sample (e.g., within its internal compartment) and add a composition thereto.

[0108] In some embodiments, the compositions in the kit may be substantially free or devoid of microbial contamination (as described above).

[0109] Various sample collection devices are described in the following applications, each of which is specifically incorporated herein by reference in its entirety: U.S. Provisional Patent Application No. 14 / 952,712, filed November 25, 2015; U.S. Provisional Patent Application No. 62 / 370,630, filed August 3, 2016; U.S. Provisional Patent Application No. 62 / 453,459, filed February 1, 2017; U.S. Provisional Patent Application No. 62 / 510,174, filed May 23, 2017; U.S. Provisional Patent Application No. 62 / 512,513, filed May 30, 2017; No. 94, U.S. Provisional Patent Application No. 62 / 513,235, filed May 31, 2017, U.S. Provisional Patent Application No. 62 / 529,355, filed July 6, 2017, U.S. Provisional Patent Application No. 15 / 667,228, filed August 2, 2017, International Application Serial No. PCT / US2017 / 045352, filed August 3, 2017, U.S. Provisional Patent Application No. 15 / 692,259, filed August 31, 2017, and U.S. Provisional Patent Application No. 62 / 590,165, filed November 22, 2017.

[0110] The compositions of the present disclosure may be incorporated into a device described in any of the aforementioned applications.Embodiments of the present disclosure may include a kit that includes a composition disclosed and / or described herein and a sample collection device described in any of the aforementioned applications.

[0111] Manufacturing method Some embodiments include a method of producing the composition of the present disclosure. The embodiments may include providing or obtaining a carrier as described herein. The embodiments may include adding an appropriate amount of one or more components or ingredients as described herein (e.g., to a final concentration as described herein) to the carrier. The embodiments may include adding a stock solution of one or more components or ingredients as described herein in a stated amount to the carrier.

[0112] At least one embodiment includes adding a chaotropic agent, a buffer, a chelating agent, a surfactant, an alcohol, an acid, and / or a mucolytic agent to the carrier. One or more embodiments may include adding a visual indicator to the carrier. At least one embodiment includes adding a chaotropic agent to a final concentration of 20-50% (w / w), a buffer to a final concentration of 0.1-5% (w / w), a chelating agent to a final concentration of 0.01-5% (w / w), a surfactant to a final concentration of 0.01-5% (w / w), an alcohol to a final concentration of 5-25% (w / w), an acid to a pH of 6.5-9.5 or an equivalent amount, and / or a mucolytic agent to a final concentration of 0.005-0.25% (w / w) to the (liquid) carrier. At least one embodiment includes adding a visual indicator to a final concentration of 0.00005-0.5% (w / w) to the (liquid) carrier. The carrier may be present in any amount up to 100%.

[0113] At least one embodiment includes adding to the (liquid) carrier a chaotropic agent to a final concentration of (about) 43.92% (w / w), a buffer to a final concentration of (about) 2.65% (w / w), a chelating agent to a final concentration of (about) 0.81% (w / w), a surfactant to a final concentration of (about) 0.279% (w / w), an alcohol to a final concentration of (about) 17.73% (w / w), an acid to a pH of (about) 6.5-9.5 or to a final concentration of (about) 0.4% (w / w), and / or a mucolytic agent to a final concentration of (about) 0.093% (w / w). At least one embodiment includes adding to the (liquid) carrier a visual indicator to a final concentration of (about) 0.00037% (w / w). The carrier may be present in an amount of (about) 34.12% or up to 100%.

[0114] In some embodiments, the chaotropic agent may be or include guanidine and / or thiocyanate, the buffering agent may be or include Tris or Trizma base, the chelating agent may be or include EDTA or disodium EDTA (salt) dihydrate, the surfactant may be or include SLS, the alcohol may be or include ethanol and / or isopropanol (e.g., SDA 3C), the mucolytic agent may be or include N-acetyl-L-cysteine, the acid may be or include HCl, the carrier may be or include water, and / or the optional visual indicator may be or include FD&C Blue No. 1.

[0115] Methods of making a nucleic acid stabilizing and / or preservation composition can include adding a carrier to a container (e.g., filling a mixing tank with (filtered, deionized, etc.) water). In some embodiments, the carrier can be included in an amount appropriate for a final concentration of about 34.12% (w / w) or up to 100% of the composition.

[0116] In some embodiments, the mixer may be operated before the one or more additional components or ingredients are added to the carrier. In some embodiments, the mixer may be operated after the one or more additional components or ingredients are added to the carrier. In some embodiments, the mixer may be set at a speed setting of 2 to 8, preferably 3 to 7, more preferably 4 to 6, even more preferably 5, and / or a sweep setting of 2 to 8, preferably 3 to 7, more preferably 4 to 6, even more preferably 5. In some embodiments, the carrier may be heated to a suitable mixing temperature before the one or more additional components or ingredients are added to the carrier. In some embodiments, the carrier may be heated to a suitable mixing temperature after the one or more additional components or ingredients are added to the carrier. In some embodiments, the suitable mixing temperature may be (about) 55 to 95±5°F, preferably 60 to 90±5°F, more preferably 65 to 85±5°F, even more preferably 70 to 80±5°F, and most preferably 75±5°F.

[0117] In some embodiments, a suitable amount of chaotropic agent (e.g., guanidine thiocyanate) may be added to the carrier (e.g., to a final concentration of the composition of about 43.92% (w / w)). In some embodiments, the chaotropic agent may be mixed in the carrier for a period of time (e.g., 30-300 minutes, preferably 60-240 minutes, more preferably 120-180 minutes, even more preferably 140-160 minutes, and most preferably 150 minutes, or until the chaotropic agent has dissolved in solution).

[0118] In some embodiments, a suitable amount of buffering agent (e.g., Tris or Trizma base) may be added to the carrier (e.g., to a final concentration of the composition of about 2.65% (w / w)). In some embodiments, the buffering agent may be mixed in the carrier for a period of time (e.g., 1-90 minutes, preferably 5-60 minutes, more preferably 10-45 minutes, even more preferably 12-30 minutes, even more preferably 15-25 minutes, and most preferably (about) 20 minutes, or until the buffering agent goes into solution).

[0119] In some embodiments, a suitable amount of a chelating agent (e.g., EDTA, EDTA disodium salt, EDTA disodium (salt) dihydrate) may be added to the carrier (e.g., to a final concentration of about 0.81% (w / w) in the composition). In some embodiments, the chelating agent may be mixed in the carrier for a period of time (e.g., 1-90 minutes, preferably 5-60 minutes, more preferably 10-45 minutes, even more preferably 12-30 minutes, even more preferably 15-25 minutes, and most preferably (about) 20 minutes, or until the chelating agent is dissolved in solution). In at least one embodiment, the buffer and the chelating agent may be added to the carrier together at (about) the same time, contemporarily, concomitantly, and / or (substantially) concurrently (or simultaneously), with or without prior mixing together. In some embodiments, the buffer and the chelating agent may be added to the carrier separately.

[0120] In some embodiments, a suitable amount of surfactant (e.g., SLS) may be added to the carrier (e.g., to a final concentration of about 0.279% (w / w) in the composition). In some embodiments, the surfactant may be mixed in the carrier for a period of time (e.g., 1-90 minutes, preferably 5-60 minutes, more preferably 10-45 minutes, even more preferably 15-35 minutes, even more preferably 20-30 minutes, and most preferably (about) 25 minutes, or until the surfactant goes into solution).

[0121] In some embodiments, an appropriate amount of alcohol (e.g., to a final concentration of about 17.73% (w / w) in the composition) (e.g., ethanol, a mixture of ethanol and another chemical such as isopropanol, or SDA, preferably SDA 3C) may be added to the carrier. In some embodiments, the alcohol may be mixed in the carrier for a period of time (e.g., 5-90 minutes, preferably 10-75 minutes, more preferably 15-60 minutes, even more preferably 25-45 minutes, even more preferably 30-40 minutes, and most preferably (about) 35 minutes, or until the alcohol has gone into solution).

[0122] In some embodiments, an optional visual indicator (e.g., a colorant, dye, preferably a blue dye such as FD&C Blue No. 1) in a suitable amount (e.g., to a final concentration of the composition of about 0.00037% (w / w)) may be added to the carrier. In some embodiments, the visual indicator may be mixed in the carrier for a period of time (e.g., 5-90 minutes, preferably 10-60 minutes, more preferably 15-45 minutes, even more preferably 10-30 minutes, even more preferably 15-25 minutes, and most preferably (about) 20 minutes, or until the visual indicator has dissolved in solution).

[0123] In some embodiments, an appropriate amount of acid (e.g., hydrochloric acid) may be added to the carrier (e.g., to a final concentration of about 0.4% (w / w) in the composition or to bring the composition to a pH of 8.0). In some embodiments, the acid may be mixed in the carrier for a period of time (e.g., 5-90 minutes, preferably 10-60 minutes, more preferably 15-45 minutes, even more preferably 10-30 minutes, even more preferably 15-25 minutes, and most preferably (about) 20 minutes, or until the acid goes into solution and / or the mixture equilibrates at the desired pH).

[0124] In some embodiments, a suitable amount of a mucolytic (or reducing agent) (e.g., N-acetylcysteine, N-acetyl-L-cysteine) (e.g., to a final concentration of the composition of about 0.093% (w / w)) may be added to the carrier. In some embodiments, the mucolytic agent may be mixed in the carrier for a period of time (e.g., 5-90 minutes, preferably 10-60 minutes, more preferably 15-45 minutes, even more preferably 10-30 minutes, even more preferably 15-25 minutes, and most preferably (about) 20 minutes, or until the mucolytic agent goes into solution and / or the mixture equilibrates at the desired pH).

[0125] An exemplary series of manufacturing batch procedures is shown in Table 3.

[0126] [Table 3]

[0127] Quality control testing may be performed at any appropriate point during production. For example, upon completion of the bulk manufacturing process for each batch, two samples (approximately 4 ounces each) were aseptically obtained from the bulk mix tank using clean, sanitary, and approved appropriate tools to obtain samples from each of the following locations: top of the batch near the center of the tank, top of the batch near the side wall of the tank, center of the batch near the center of the tank, center of the batch near the side wall of the tank, bottom of the batch near the center of the tank, and bottom of the batch near the side wall of the tank. Each sample was placed in a sterile cup and labeled.

[0128] Each sample was tested for proper appearance, specific gravity, and pH. Additionally, assays were performed to test the synergy and / or effectiveness of chelating agents, alcohol, and mucolytic agents. Additionally, contamination (microbial limits) was tested by measuring total aerobic plate counts, yeast and mold, Staphylococcus aureus, and Pseudomonas aeruginosa. Table 4 shows the test specifications for the various quality control measurements.

[0129] [Table 4]

[0130] In some embodiments, the method can include sealing the composition in a suitable storage container or part of a sample collection device (e.g., a composition reservoir in a container or vial (e.g., tube)). Samples were also subjected to controlled room temperature (CRT) and accelerated (ACC) stability testing in the storage container and sample collection device.

[0131] In some embodiments, the methods may produce or result in compositions that may be substantially free or devoid of microbial contamination (as described above).

[0132] How to use Some embodiments include a method of preserving and / or stabilizing nucleic acid. The method may include obtaining a biological sample containing nucleic acid and combining a composition of the present disclosure with the biological sample. In at least one embodiment, the biological sample may be a mucin-containing body fluid or tissue, such as sputum or saliva. The method may include reducing the viscosity of the mucin-containing body fluid or tissue (e.g., by reducing disulfide bonds inherent in mucins using a mucolytic or reducing agent).

[0133] In at least one embodiment, the nucleic acid is DNA. In some embodiments, the composition can stabilize the nucleic acid or DNA (e.g., against degradation). In some embodiments, the composition can stabilize the nucleic acid or DNA for a first period of time. In some embodiments, the first period of time can be about 14 days, 30 days, 60 days, 90 days, 120 days, 240 days, 300 days, or 365 days or more. In some embodiments, the composition can stabilize the nucleic acid or DNA for a first period of time at room temperature, -20°C to 50°C, or other suitable temperature or temperature range. In some embodiments, the composition can stabilize for a second period of time. In some embodiments, the second period of time can be about 12 months, 18 months, 24 months, 30 months, or 36 months or more. In some embodiments, the composition can stabilize for a second period of time at room temperature, -20°C to 50°C, or other suitable temperature or temperature range.

[0134] At least one embodiment includes a method of recovering nucleic acid from sputum, comprising: i) obtaining sputum from a subject; ii) contacting the sputum with a composition of the present disclosure to form a sample mixture; iii) optionally contacting the mixture with a protease; and iv) recovering nucleic acid from the mixture.

[0135] In some embodiments, the composition, when added in an appropriate amount to a biological sample, does not significantly inhibit or interfere with subsequent nucleic acid analysis, such as DNA amplification (by PCR), (next generation) sequencing, etc.

[0136] Sampling Some embodiments of the present disclosure include obtaining, obtaining, and / or harvesting a biological sample (e.g., from a subject, such as a human subject). In some embodiments, the biological sample may be or may include (human) saliva. The (human) sample may be collected aseptically (to avoid (microbial) contamination). In one or more embodiments, the sample may be collected in a sample collection device or its sample container. In some embodiments, the sample collection device or container may be part of a kit and / or may include a composition of the present disclosure. An embodiment may include contacting the sample with a composition of the present disclosure.

[0137] DNA extraction and analysis Some embodiments of the present disclosure include extracting nucleic acids from a biological sample. Below is a non-exhaustive list or description of various modes of extraction or extraction procedures that may be suitable for use with the compositions of the present disclosure.

[0138] extraction chemistry Organic phenol-chloroform extraction is still the mechanism employed in both the research and clinical laboratories, depending on the sample type with respect to tissue source. To extract high molecular weight genomic DNA, manual phenol / chloroform extraction is performed, followed by a chloroform back extraction to aid in the removal of organic solvent contamination.

[0139] Salting out - Both homemade and commercial salting out chemistry are widely used for high molecular weight nucleic acid extraction. This approach requires the addition of high concentrations of salt to the saliva sample to destroy the nucleic acids under the addition of ethanol. Prior to analysis, a series of washes are performed to remove excess salt from the sample.

[0140] Solid Phase - Various technology providers offer both spin column and vacuum manifold solutions to bind DNA to a solid support for nucleic acid purification. Once the DNA is attached to the support, a series of washes are performed. Finally, a small amount of DNA is eluted from the solid support for analysis. Spin column chemistry is frequently used in both research and clinical laboratories.

[0141] Bead-based - beads or (para)magnetic beads are prepared with various binding moieties or by charge to bind high molecular weight DNA. The beads are captured by a magnetic field so that those not bound to the beads can be washed away as part of the purification process. Once washing is complete, the nucleic acid is eluted from the beads using a solution that solubilizes the DNA, after which the remaining beads are removed by reapplication of the magnetic field. There are both small and large volume automated solutions for this approach in research and clinical environments.

[0142] Exemplary Extraction Ten DNA samples previously extracted from the saliva collection kit containing the composition of the present disclosure, and up to six samples from existing saliva collection kits were used in the test.An additional 23 samples were newly collected using the saliva collection kit of the present invention.Each of the 23 samples was extracted in duplicate 700μl aliquots.Standard QC was performed to assess DNA quality.

[0143] 23 / 23 samples were extracted with two replicates per sample. The average combined yield by UV spectrophotometry (Nanodrop) for all samples was 20.4ug (range 2.8-111.4). 20 / 23 extractions had a 260 / 280 ratio, lower than the desired value of 1.7, although the three samples lower than 1.7 are likely to perform well in downstream analyses. All samples had high molecular weight DNA, as shown in Figure 1A.

[0144] 700 μl of saliva sample solution was extracted using Perkin Elmer reagent for MSM1 (Chemagen) extraction system. Concentration of all samples was determined by UV spectrophotometry (Nanodrop). Purity estimates were determined UV spectrophotometry by measuring the A260 / A280 absorbance ratio. Additionally, samples were analyzed on agarose gels to visualize sample integrity. A molecular weight sizing ladder (L) and a control sample over 50 kb (C) were included in each gel. Bionexus universal HI-LO DNA markers used for qualitative gels (see Figure 3B).

[0145] Analytical approach Some embodiments include analyzing the extracted nucleic acid. Several methods are available for analyzing the extracted nucleic acid. The following is a non-exhaustive list or description of various methods for analyzing the extracted nucleic acid that may be suitable for use with the compositions of the present disclosure.

[0146] PCR Polymerase chain reaction (PCR) analysis is a rapid and cost-effective method to assess the fidelity and purity of DNA templates. A series of PCR reactions (amplicons of various sizes) are generated from every DNA template and electrophoretically separated for amplification products of the correct size. The range of PCR amplicon sizes provides information about the fidelity of every DNA extraction product.

[0147] qPCR Quantitative PCR (qPCR) uses dual-labeled fluorescent probes for quantification of PCR amplicons. Allelic discrimination utilizing Taqman chemistry will be used to determine the specific genotype for all DNA harvested and extracted across all extraction approaches. Each subject's genotype will be measured for concordance across all variables being analyzed. All quantitative measurements will be performed in triplicate.

[0148] dPCR Digital PCR (dPCR) is a new technology that is being employed for sensitive detection of genotypes in samples with limited quantity and / or limited quality. The same Taqman assay is used to determine the absolute sensitivity of all extracted DNA samples. Given the sensitivity of dPCR, the final sensitivity for each variant being analyzed can be determined.

[0149] Microarrays When it comes to both discovery and clinical classification of a single DNA sample, the measurement of hundreds of thousands or millions of SNPs simultaneously is of great significance. The requirements for sensitivity and specificity are quite different from QPCR-based assays, and the approach for SNP detection is also different since this analytical approach uses a hybridization-based mechanism to identify DNA variants. Call rates and SNP concordance between donors treated with different DNA extraction chemistries are important analytical endpoints.

[0150] Sanger sequencing In this study, a gold standard for mutation analysis is employed across all samples. Target regions for analysis cover the same amplicons for QPCR, dPCR and microarray to cross-validate genotypes across all other analytical methods. The ability to make high-quality Sanger base calls (and therefore variants) is highly dependent on the quality of the nucleic acid. This approach is routinely used for clinical analysis.

[0151] NextGen Sequencing As used herein, "next-generation sequencing" (NGS), also known as high-throughput sequencing, refers to non-Sanger-based high-throughput DNA sequencing technology.Through NGS, millions or even billions of DNA strands can be sequenced in parallel, resulting in substantially higher throughput and minimizing the need for fragment cloning methods that are often used in genome Sanger sequencing.NGS is an umbrella term used to describe several modern sequencing technologies or platforms, including, for example, pyrosequencing, sequencing by synthesis, sequencing by ligation, ion semiconductor sequencing, and others known in the art.

[0152] As will be appreciated by those skilled in the art, NGS generally allows for the sequencing of large amounts of DNA and RNA much faster and cheaper than Sanger sequencing. In NGS, a huge number of short reads are sequenced in one stroke. To do this, the input sample can first be divided into short sections. The length of these sections depends on the specific sequencing mechanism used. Illustrative examples of specific NGS technologies include, for example, Illumina® (Solexa) sequencing, Roche 454™ sequencing, Ion torrent™: Proton / PGM sequencing, SOLiD sequencing, etc.

[0153] In Illumina sequencing, reads of 100-150 bp are used. Somewhat longer fragments are ligated to a common adapter and annealed to the slide using the adapter. PCR is performed to amplify each read, creating spots with many copies of the same read. They are then separated into single strands and sequenced. The slide is flooded with nucleotides and DNA polymerase. These nucleotides are fluorescently labeled with the color that corresponds to the base. They also have terminators, so only one base is added at a time. An image of the slide is taken. At each read position, there is a fluorescent signal indicating the base that was added. The slide is then prepared for the next cycle. The terminator is removed, allowing the next base to be added, and the fluorescent signal is removed, preventing the signal from contaminating the next image. This process is repeated, adding one nucleotide at a time and imaging in between. A computer is then used to detect the base at each site in each image and use these to build a sequence. The read length depends on the number of cycles performed, so all sequence reads will be the same length.

[0154] Roche 454™ sequencers can generally sequence much longer reads than Illumina®. Like Illumina®, it does this by sequencing multiple reads at once by reading a light signal as a base is added. Like Illumina®, the DNA or RNA is fragmented into shorter reads, in this case up to 1kb. The fragments are then amplified by PCR using adaptor-specific primers. Each bead is then placed into a single well of a slide. So each well contains a single bead and is covered with many PCR copies of a single sequence. The well also contains DNA polymerase and sequencing buffer. The slide is flooded with one of the four NTP species. If this nucleotide is next in the sequence, it is added to the sequence that was read. If that single base is repeated, then more are added. So if it is flooded with a guanine base and the next part of the sequence is a G, then one G is added, but if the next part of the sequence is GGGG, then four Gs are added. The addition of each nucleotide emits a light signal. The location of these signals is detected and used to determine which bead a nucleotide is added to. This NTP mix is ​​washed away. The next NTP mix is ​​added and the process is repeated cycling through the four NTPs. This type of sequencing produces a graph for each sequence read, showing the signal density for each nucleotide wash. The sequence can then be computationally determined from the signal density at each wash. Because a different number of bases are added with each cycle, all read sequences resulting from the 454 will be of different lengths.

[0155] Unlike Illumina® and Roche 454™, Ion torrent™ and Ion proton sequencing do not utilize an optical signal. Instead, they utilize the fact that the addition of dNTPs to a DNA polymer releases H+ ions. As with other types of NGS, the input DNA or RNA is fragmented, this time to ~200bp. Adapters are added and one molecule is placed on a bead. The molecule is amplified on the bead by emulsion PCR. Each bead is placed into a single well of a slide. Like Roche 454™, the slide is flooded with a single species of dNTP, one NTP at a time, along with buffer and polymerase. Each H+ ion released lowers the pH, so the pH is detected in each well. The change in pH allows the determination of which base, and how much of it, has been added to the sequence being read. The dNTPs are washed away and the process cycles repeatedly through different dNTP species. The change in pH, if any, is used to determine how many bases (if any) have been added with each cycle.

[0156] Additionally or alternatively, sequencing may be performed more generally by fluorescence-based sequencing techniques and / or any current-based sequencing techniques. Illustrative examples of fluorescence-based sequencing techniques include any technique that incorporates fluorophore-linked nucleotides, such as sequencing using Illumina®-based sequencing methods and systems. Illustrative examples of current-based sequencing techniques include any sequencing technique (including strand sequencing) that measures the current of a polynucleotide as it passes through a pore inserted in a charged membrane or otherwise specifically disrupts the current of a sensor and / or a charged membrane. Non-limiting examples of current-based sequencing techniques include the Nanopore DNA sequencing system and the Oxford NanoPore Technologies® method.

[0157] Strand sequencing systems such as those provided by Oxford NanoPore Technologies® offer several advantages when determining copy number variations of nucleic acids, particularly copy number variations of samples potentially containing DNA (or other nucleic acids) from neoplastic and / or cancerous cells. For example, in strand sequencing techniques, single portions of the genome are sequenced continuously, which allows for direct analysis of copy number variations instead of the implicit analysis of copy number variations that may occur when analyzing sequencing data provided by other sequencing methods in which the sample nucleic acid is cut into small fragments for sequencing. This may be particularly advantageous for embodiments where sequence coverage is low. That is, in some embodiments, a low sequence coverage run may return an incomplete set of genomic data. From the sequence data, it may be possible to infer the presence and / or absence of genomic regions in addition to the implicit copy number for each sequence region. However, in strand sequencing methods, the long sequence reads generated may allow for a more conclusive assessment of copy number variations, especially for regions that are duplicated or deleted. When the full sequence is not available due to low coverage of the sequencing run, it can be difficult to determine which parts of the genome were deleted (in the form of copy number variation) versus which parts of the genome were not represented based on statistical probability (i.e., random sampling).

[0158] As an illustrative example, a sequencing run that produces data with 0.5x coverage would theoretically leave half of the sample unrepresented. Using a sequencing method that "chops up" the nucleic acid into small fragments for sequencing, the end product may be a sequence library that represents about half of the entire reference genome, with the aligned reference genome interspersed with a smattering of smaller nucleic acid matches. On the other hand, using strand sequencing, again at low coverage (e.g., 0.5x), the result may still be a sequence library that represents about half of the entire reference genome. However, when aligned to the reference genome, the matched portions may be much longer and provide more definitive information such as which sequences have been deleted, duplicated, inserted, etc. This, too, may be problematic. Longer continuous portions of the genome may be represented by strand sequencing approaches, but long continuous portions of the genome also remain unknown. Thus, while strand sequencing may allow for a finer view of portions of the genome, smaller sequencing reads have the potential to provide a more comprehensive picture of the entire genome. In this and other ways, strand sequencing may provide a robust model for analyzing copy number variations.

[0159] The above are illustrative of known sequencing technologies and their application to the methods and systems of the present invention disclosed herein, which have not yet been discovered or otherwise disclosed. That is, the sequencing method itself is not a necessary inventive step in many embodiments (e.g., unless improvements are provided to the method and / or system through the use of a particular sequencing technology); rather, what is done with the sequencing data provided by the sequencing method and / or how those data are applied generally involves an inventive step. Therefore, it should be understood that future sequencing technologies (and those sequencing technologies not explicitly listed herein) are included within the scope of this application when used as tools in the disclosed methods or systems.

[0160] Additionally, any of the aforementioned sequencing techniques can be used with any number of flow cells or other similar inputs, in any number or capacity that affects the total number of sequencing reads provided for each sequencing reaction / run.

[0161] Next-generation sequencing may eventually become the standard for analyzing both DNA and RNA targets. Target panels, including genomic regions covered by qPCR, dPCR, and array-based targets, are created for all DNA samples through a standard library preparation process. Samples are barcoded and multiplexed on the NextGen platform for variant analysis. Data is demultiplexed and analyzed for direct comparison of genotype calls across all other platforms.

[0162] Several of the above and other DNA-based downstream methods were tested to evaluate the quality and usefulness of DNA extracted from samples collected using a 2mL saliva collection kit containing the nucleic acid preservative composition of the present disclosure. In addition, a small number of DNA samples extracted from two existing products were used to compare several downstream methods. The following is a non-exhaustive listing or description of several downstream methods that were tested, including single nucleotide polymorphisms (SNPs) using the OpenArray® format (n=120 SNPs / sample), TaqMan® chemistry for detection of copy number variants (CNVs) using TaqMan® chemistry (CYP2D6 gene), whole exome next generation sequencing (WES) (Thermo Fisher) and chromosomal microarray analysis (CMA) (Affymetrix CytoScan HD). These methods were selected to include a wide variety of common methods used in molecular genetic laboratories. In addition to downstream analysis, bacterial DNA content as a percentage of total DNA was measured using a quantitative PCR (qPCR) assay. Without being bound by any theory, it is known that saliva samples have high concentrations of bacterial DNA that can be an interference with some methods.

[0163] TaqMan® OpenArray® SNP Genotyping: Genotyping of single nucleotide polymorphisms was performed using TaqMan® OpenArray® genotyping assays. The TaqMan® assay is an allelic discrimination assay using PCR amplification and a pair of fluorescent dye detectors targeting SNPs. One fluorescent dye is attached to the detector that perfectly matches the first allele (e.g., the "A" nucleotide) and a different fluorescent dye is attached to the detector that perfectly matches the second allele (e.g., the "C" nucleotide). During PCR, the polymerase releases a fluorescent probe into the solution that is detected using Life Technologies, Inc.'s end-point analysis. Specifically, the OpenArray® technology is a nanoliter fluidics platform for small volume, liquid-phase reactions. The OpenArray® technology uses a microscope slide-sized plate with 3,072 through-holes. Each through-hole is 300 μm in diameter and 300 μm deep and is treated with hydrophilic and hydrophobic coatings. The TaqMan® chemistry for a single assay is preloaded into each through-hole and dried. OpenArrays® were obtained through design and manufacturing by Life Technologies. Genotyping was performed using Taqman Genotyper v1.0.1 software from Life Technologies.

[0164] A total of 5234 genotypes were determined for 44 samples for 118-120 SNPs / sample. The 44 samples included three sample replicates each from extractions from both the inventive kit and the existing kit. Genotyping of samples from the inventive kit was highly successful and exceeded known performance expectations for this type of assay. Without being bound by any theory, Taqman genotyping is expected to successfully genotype greater than 99% of samples. In this experiment, 99.75% of samples produced a genotype (5221 / 5234). There was no significant difference between the inventive solution DNA extract and the existing extract at genotyping rates of 99.74% and 99.87%, respectively. In the six duplicate samples in both the inventive solution DNA extract and the existing extract, all genotypes were consistent.

[0165] Taqman® Copy Number Variant Detection: The TaqMan® copy number assay (CYP2D6-Hs00010001_cn) was used to detect copy number of the CYP2D6 gene, a well-characterized CNV evaluated in pharmacogenetics. The TaqMan® copy number assay uses TaqMan® MGB probe chemistry to assess copy number of a genomic DNA target. The assay used an AppliedBiosystems® 7900 HT real-time PCR instrument and copy caller software to determine copy number. Each sample was amplified in triplicate and plotted against a standard curve to determine copy number.

[0166] Thirty-three of the inventive extracted DNA samples and five of the existing extracted samples were analyzed for well-characterized copy number variants in the CYP2D6 gene. 30 / 33 of the inventive solution extracted DNA samples produced CNV results. 5 / 5 of the competitor extracted samples produced CNV results. The three samples that did not produce CNV results were all from the same person ("B") from three independent samples taken on the same day. A sample from this same individual taken on a different day and extracted from an existing saliva kit produced a normal CNV result, ruling out potential interfering mutations.

[0167] Whole Exome Sequencing (WES): Exome libraries were prepared using the Ion AmpliSeq™ Exome Kit. The library kit was combined with the Ampliseq Exome Panel Primer Pool, which contains approximately 294,000 primer pairs across 12 primer pools. The resulting target amplicons were then treated with a reagent to partially digest the primers and phosphorylate the amplicons. The amplicons were then ligated to ion adapters using barcodes and purified. Upon completion of exome library preparation, the purified, exome-enriched libraries were quantified by real-time PCR. The quantified libraries were then diluted to 100 pM and used to prepare templated Ion PI™ Ion Sphere™ Particles (ISPs) for sequencing. Samples were then sequenced on the Ion Proton System using the Ion PI™ Chip v3. Ion Hi-Q Sequencing 200 V2 chemistry was used to sequence average insert libraries up to 200 base pairs.

[0168] Of the four samples, three samples extracted from the saliva kit of the present invention and one sample extracted from the existing saliva kit were evaluated by whole exome library preparation (AmpliSeq Exome, Thermo Fisher) followed by next generation sequencing on an Ion Proton instrument (Thermo Fisher). Typically expected results are more than 30 million reads, an average coverage depth of more than 80x, and more than 80% of the bases covered at a depth of more than 20x. Three of the four samples met these criteria. There was one saliva kit extracted sample of the present invention that did not meet two of the three QC metrics with less than 30 million reads and an average depth coverage of less than 80x. Note that the poorly performing sample was one of the same samples that did not have a successful CNV analysis as well. Examination of the DNA QC profile showed something abnormal for this sample. All QC metrics were met. Although this sample performed poorly, adequate exome sequencing results were obtained for evaluation.

[0169] Chromosomal Microarray (CMA): CMA analysis was performed using the Affymetrix CytoScan HD assay according to the manufacturer's protocol. Samples were scanned on a Genome Analyzer 3000. Chromosomal microarrays were used to detect chromosomal abnormalities with higher resolution than karyotyping. The assay consists of DNA preparation followed by hybridization to CytoScan HD chips, which contain approximately 2.7 million CNVs across the genome. Samples were evaluated using Affymetrix ChAS software.

[0170] One sample was selected from Spectrum saliva kit extracted DNA, which was successfully evaluated by chromosomal microarray (Affymetrix, CytoScan HD). The sample had a MAPD value <0.25 (0.18), SNPQC value >15 (16.47), waviness value <0.12 (0.09), and QC call rate >95% (96.8%).

[0171] Bacterial DNA content using qPCR assay Bacterial DNA content in samples was determined using a modified protocol described in the literature. Briefly, a standard curve was created using serial dilutions of E. coli for comparison with the generated real-time PCR data. PCR primers were selected from a region of the 16S rRNA gene known to be conserved across a wide variety of microorganisms and not found in eukaryotic DNA. DNA was tested for the presence of the 16S rRNA gene using real-time qPCR on a ThermoFisher 7900HT instrument using copy-caller software.

[0172] It has been thought that bacterial DNA content as a percentage of the total amount of DNA from a saliva collection sample would possibly inhibit or reduce the success rate of downstream analysis. Thirty-three DNA samples extracted from the saliva kit of the present invention and five DNA samples extracted from existing saliva kits were tested for the percentage of bacterial DNA present. Previous data from competitors estimated the percentage of bacterial DNA to be approximately 13%. The average bacterial content of the saliva kit extracts of the present invention was 5.5% (1.1-14.3%). The average bacterial content of the saliva kit extracts from competitors was 26% (2.1-96.2%) to 14.31%.

[0173] A series of these and / or other experimental tests were conducted to support an FDA submission for 510K review to obtain approval for use of the formulations of the present disclosure in a collection device for nucleic acid extraction using any one of a variety of available chemical approaches, including organic extraction, solid phase extraction, bead-based extraction, and salting-out extraction, as well as any one of a variety of currently used molecular analyses, including PCR, qPCR, dPCR, microarray, Sanger sequencing, and so-called next generation (or NextGen) sequencing (NGS), as outlined in Table 5 below.

[0174] [Table 5]

[0175] Summary of results DNA was successfully extracted from all samples in all replicates. In general, the size (and yield) of the extracted DNA was high. There was only little evidence of degradation. Replicates from samples were very similar in terms of yield. Furthermore, yields across what are assumed to be the same individual performed similarly. Genotyping for SNPs produced high quality results and met expected yields. No sample from one individual, four separately collected samples, met QC metrics for CNV (n=3) or NGS (n=1). Bacterial DNA content as a percentage of total DNA was relatively low in our saliva kit DNA extracts.

[0176] In a further example shown in Tables 6 and 7, 100 samples were used to test the performance of the nucleic acid storage composition of the present disclosure ("Invention") and two existing products ("Existing 1" and "Existing 2"). As shown in Table 6, the nucleic acid storage composition of the present disclosure "Invention" resulted in a higher average DNA concentration and a higher amount (yield) of total DNA than either of the "Existing" products.

[0177] [Table 6]

[0178] Furthermore, as shown in Table 7, samples treated with the nucleic acid preservation composition of the "invention" disclosure had a significantly lower average amount of non-human DNA than any of the "existing" products.

[0179] [Table 7]

[0180] Thus, the compositions of the present disclosure are surprisingly and significantly superior to existing DNA preservation products. Specifically, it was surprising and unexpected that the compositions of the present disclosure work so well (e.g., obtain large amounts of (human) nucleic acid (DNA) and / or have or exhibit low levels of microbial contamination). It was even more surprising and unexpected that the compositions of the present disclosure work so well with the small amounts of alcohol provided in some embodiments. For example, in some embodiments, the amount of alcohol included in the composition may be less than typical, traditional, or existing nucleic acid preservation solutions (e.g., less than about 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, or 60%). Furthermore, the lower amount of alcohol is more economical and / or makes the composition more amendable for shipping or transportation (e.g., by making it easier to comply with shipping requirements and regulations, reduce volatility, etc.).

[0181] conclusion It will be understood that certain embodiments (e.g., compositions, kits, methods, etc.) may include, incorporate, or include features (e.g., properties, components, ingredients, elements, members, parts, steps, etc.) described in other embodiments disclosed and / or described herein. Various features of one embodiment may be compatible, combined, included, and / or incorporated with other embodiments of the present disclosure. Thus, the disclosure of a particular feature in relation to one embodiment of the present disclosure should not be construed as limiting the application or inclusion of that feature to the particular embodiment. Rather, it will be understood that other embodiments may also include that feature without necessarily departing from the scope of the present disclosure. Furthermore, any feature described herein may be combined with any other feature of the same or different embodiments disclosed herein, unless the feature is described as requiring another feature in combination therewith.

[0182] The described embodiments should be considered in all respects as merely illustrative and not restrictive. Thus, the scope of the present invention is indicated by the appended claims, rather than by the foregoing description. All changes that come within the scope and meaning of the claims are to be embraced therein. Various changes and / or modifications of the features illustrated herein and additional applications that would occur to one skilled in the art and possess this disclosure may be made to the illustrated embodiments without departing from the spirit and scope of the present invention as defined by the claims, and should be considered within the scope of this disclosure. Although various features and embodiments are disclosed herein, other features and embodiments are also contemplated. For example, well-known features and embodiments are not specifically described herein in order to avoid obscuring aspects of the described embodiments. However, such features and embodiments are also contemplated herein.

Claims

[Claim 1] 1. A human nucleic acid storage composition comprising: 43.92%±10% (w / w) guanidine thiocyanate; 2. 65%±10% (w / w) tris(hydroxymethyl)aminomethane (Tris); 0.81%±10% (w / w) of ethylenediaminetetraacetic acid (EDTA) or disodium EDTA (salt) dihydrate; 0.279%±10% (w / w) sodium lauroyl sarcosinate (SLS); 17.73%±10% (w / w) alcohol, including a mixture of about 95%±10% (v / v) ethanol and about 5%±10% (v / v) isopropanol; 0.093%±10% (w / w) N-acetyl-L-cysteine; With an appropriate amount of hydrochloric acid (±10%) to a pH of about 8.0, and an aqueous carrier comprising up to 100% filtered, purified, distilled, and / or deionized water.